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Duchenne muscular dystrophy (DMD) is a fatal genetic disorder caused by mutations in 
the gene coding for dystrophin protein, which give rise to a dysfunctional protein in skeletal 
muscle. Dystrophic muscle progressively degenerates. In addition, necrotic muscle fibers 
undergo high levels of inflammation that in turn promote the pathology that is associated with 
this devastating disease. Therefore, treatments that 1) restore expression a functional dystrophin 
protein in dystrophic muscles, and 2) lower the ongoing inflammation in the necrotic muscle 
tissue, are both important in ameliorating DMD phenotype. Transfer of a functional dystrophin 
gene using a viral vector can help restore the missing dystrophin protein in dystrophic muscles. 
The host immune system, however, is a major barrier to successful vector-mediated dystrophin 
protein expression in a dystrophic host, as anti-dystrophin immune response leads to rejection of 
the protein. Here I show that temporal elimination of the host immune system by irradiation in 
the mdx mouse, a murine model of DMD, prior to vector-mediated dystrophin gene delivery, 
leads to a delayed and diminished host anti-dystrophin immune response. These findings are 
important for a better evaluation of anti-dystrophin immunity in a dystrophic host. In the case of 
lowering inflammation in dystrophic muscles, I investigated the effects of rapamycin, a potent 
immunosuppressant, on both dystrophic phenotype and dystrophin gene transfer in mdx mice. 
Treatment of adult mdx muscles with rapamycin lead to significantly lower levels of muscle fiber 
necrosis and reduced effector T cell infiltration in dystrophic muscles. These events correlated 
with a difference in activation of the mammalian target of rapamycin (mTOR) in the diaphragm 
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muscle, but not the TA muscle, suggesting a differential regulation of mTOR activation in the 
two tissues. Rapamycin treatment, however, did not allow for a higher level of vector-mediated 
dystrophin protein expression in treated muscles. In general, these findings shed more light on 
the effects of manipulating the immune system in a dystrophic host in terms of both reducing the 
inflammation that is associated with DMD and reducing anti-dystrophin responses following 
gene therapy, suggesting that regulation of the immune system is essential in ameliorating DMD.     
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PREFACE 
 
A famous Persian poem says:  
If the Lord closes a door by His wisdom          He will open another one by His blessings 
As a researcher, I truly experienced this poem during the time that I was pursuing my 
Ph.D. degree. Meeting the right people at the right time was what God gave me through His 
beneficence. During my years as a graduate student, there were times when a big part of my 
work seemed to be moving slowly or in the wrong direction. Fortunately, however, just when I 
was discouraged, I would meet with someone who would completely change things around for 
me, helping me re-gain my enthusiasm for my research and find my way. Now, as I write my 
Ph.D. thesis, I would like to acknowledge those “right people” whom I met at the “right time.”  
Angela Green. I met with Angie for the first time at a BGSA symposium. I was then a 
first-year student working on my thesis proposal, desperately trying to find a “theme” for my 
project. And there were the Tregs in Angie’s work! I truly enjoyed learning about them. I 
mentioned them to Dr. Clemens, and as always, she supported my ideas and that was how Tregs 
and the idea of down-regulation of the immune system became the theme in my Ph.D. project. 
Theresa Whiteside/Laura Strauss: I had just passed a huge gap after losing all of our mice 
due to an MPV break-out in our animal facility, and was in the middle of another gap, trying 
endlessly with no apparent success to make a vector that was to be used in Treg expansion 
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assays. I met with Dr. Whiteside and her then post-doctoral fellow, Laura, at an immunology 
seminar, as they presented their work on using rapamycin to expand Tregs. I was fortunate 
enough to be able to spend some time with Laura in their lab, learning more about rapamycin and 
their assays. Thanks to Dr. Clemens’ believing in me, learning about their work helped me add a 
completely new project to my work that turned out to be a very interesting one. 
Siddharth Jhunjhunwala: As the in vitro rapamycin studies were moving slowly, the in 
vivo work, which was the ultimate goal, seemed to be tougher that I had expected, as a very high 
number of Tregs had to be prepared and injected into the mice. I had trouble finding out how to 
control these Tregs to enter the muscle tissue; and there I was at the University of Pittsburgh 
Science 2008 event, chatting with my good friend, Rakshita, who introduced me to Sid. This 
time Sid, a graduate student working with rapamycin microparticles to deliver rapamycin in vivo 
locally, helped me with move on in my work. We talked for some time about our projects and 
shortly after mentioning it to Dr. Clemens, we became collaborators. That event extremely 
affected the speed of my work and added an interesting section to my project. 
It is needless to say that many more people have helped me and affected my work to 
make it possible for me to be where I am today. The people mentioned here are those who 
provided turning-points in my experience, making the poem mentioned at the beginning of this 
section more meaningful for me than ever. 
 
 
 1 
                            STATEMENT OF PROBLEM 
 
 
Muscular dystrophies refer to a group of genetic disorders that are associated with 
progressive muscle weakness and wasting. These diseases are due to one or more muscle protein 
defects and in general affect more than just mobility; often leading to destruction of cardiac, 
nervous, and respiratory systems as well, the latter being a result of muscle wasting in diaphragm 
tissue. An example of a common and severe muscular dystrophy that ultimately leads to an early 
death in patients is Duchenne muscular dystrophy (DMD), affecting 1 in 3,600-6,000 live male 
births per year 1-3. DMD is due to mutations in the X-linked gene coding for dystrophin protein, 
which is an essential muscle structural protein. 
 
For years gene therapy has been considered a potential way to cure DMD. Transfer of the 
large full-length dystrophin cDNA of about 11 kb has become possible due to generation of high 
capacity adenoviral (HC-Ad) vectors, which are depleted of all viral genes 4-6. Despite the 
advantages of this vector over the previously used adenoviral vectors, the host immune response 
to the vector and the therapeutic gene product is still considered a major barrier to successful 
dystrophin gene transfer 7-9. 
 
Several approaches to overcoming the problem of vector and gene product rejection by 
the host immune system have been tried, including transient blockage of immune system 
stimulation at the time of gene delivery 10, as well as delivering the vector before full maturation 
of host immune system (in the case of mice) 11-15. Nonetheless, the host’s humoral and cellular 
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immune responses against the therapeutic gene product, which ultimately reduce, if not abolish, 
therapeutic gene expression, have not been fully eliminated. It is thus crucial to understand the 
role of the host immune system in abolishing vector-mediated dystrophin protein expression in 
dystrophic muscles. 
 
 In addition to the host immune response to transferred gene product, untreated 
dystrophic muscle tissue is associated with immunological complications, such as massive 
infiltration of T cells that promote the pathology of the disease 16-18. Therefore, besides the 
genetic mutations that lead to the pathogenicity of DMD, auto-immune-like reactions in the 
damaged muscles are important factors in disease progression. Thus, it is important to better 
understand the role and pattern of immune responses in dystrophic muscles due to the disease 
and to test different approaches to ameliorate dystrophic pathology.  
 
 The subsequent pages describe studies that were performed to 1) eliminate and 
understand host anti-dystrophin immune responses to HC-Ad vector-mediated dystrophin cDNA 
transfer in dystrophic mdx mouse; 2) examine the effect of temporal local and systemic immune 
suppression on dystrophic phenotype of adult mdx mice; 3) assess the possibility of using local 
immune suppression for eliminating host immune response against vector-mediated dystrophin 
expression; and 4) evaluate the effect of muscle injury on immunity in muscle tissue. These 
studies ultimately enhance our knowledge of immune reactions in dystrophic mdx mice to both 
foreign and self-antigens, leading to approaches that may one day contribute toward a cure for 
DMD. 
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1.0  INTRODUCTION 
Copyrighted material; Part of the following section has been published: Immunology. 2009 May;127(1):1-7. and 
Ann Neurol. 2009 Sep;66(3):267-70. 
1.1 DUCHENNE MUSCULAR DYSTROPHY 
 
The most common type of muscular dystrophies is Duchenne muscular dystrophy 
(DMD), which is an X-linked recessive muscle-degenerative disorder caused by mutations, 
mostly deletions, in the largest known gene, which codes for dystrophin. Dystrophin protein has 
a molecular weight of about 427 kb 19-21 and carries out an essential structural role in muscle 
fibers. Dystrophin physically links the cytoskeleton, more specifically actin filaments, in muscle 
fibers to the extra-cellular matrix or basal lamina through its interactions with the membrane-
bound dystroglycan complex that is in turn connected to laminin in the basal lamina (Fig. 1). 
Lack of a functional dystrophin protein gives rise to an unstable muscle fiber membrane or 
sarcolemma that becomes extremely susceptible to damage due to muscle contraction.  
The unstable muscle membrane becomes “leaky” and allows for molecules travelling in 
and out of the muscle fibers; an event that can lead to necrosis of the fibers. Examples of 
molecules that can enter the cell are calcium ions (Ca++) that enter the negatively charged muscle 
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membrane and upon cell entry can lead to an overload of Ca++ in the muscle fiber cytoplasm, 
leading to cell death through necrosis 22-25. In general, an imbalance in Ca++ homeostasis has 
been linked to many pathological features in different tissues, including muscle, 25, 26 and this 
mechanism of muscle fiber damage has been considered a major one in DMD. 
 
Figure 1: Schematic of the 
dystrophin-associated proteins at the 
sarcolemma. Dystrophin and its 
associated proteins have important 
roles in maintaining muscle membrane 
or sarcolemma stability. Dystrophin 
protein, which is a crucial structural 
protein in muscle fibers links actin 
filaments to the basal lamina through 
its interactions with the membrane-
bound dystroglycan and sarcoglycan 
complexes. Absence of almost any of 
the complex-associated proteins can 
lead to an unstable membrane leading 
to muscular dystrophy. 
 
Duchenne muscular dystrophy affects approximately 1 in 3600-6000 live male births per 
year 1-3. DMD patients are usually diagnosed at around 3-5 years of age, which is when their 
physical characteristics and mobility becomes noticeably different from their peers. Parents of 
DMD patients may notice manifestations of muscle weakness, such as delayed walking, frequent 
falls, and difficulty in running, jumping, or climbing stairs. Affected boys have increased lumber 
lordosis and end up having spinal curvatures that can become very painful and sometimes need 
surgery to resolve this problem. In addition, these patients normally have a hard time standing up 
from a sitting position and normally need to push their arms against the ground or their knees in 
order to be able to stand up, a common symptom known as the Gowers’ maneuver.27 Aside from 
the physical symptoms there are other clinical symptoms associated with DMD including high 
serum levels of creatine kinase, which is a muscle-specific protein that leaks out of damaged 
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muscle fiber sarcolemma into serum 28. In addition, muscle biopsies of DMD patients, as in other 
muscular dystrophies, indicate ongoing muscle fiber necrosis, replacement of muscle tissue with 
fibrotic and fatty tissue, and infiltration of inflammatory cells in the muscle tissue.  
As the disease progresses these boys lose mobility almost completely and become 
wheelchair-dependent for movement by 10 to 12 years of age. Although inevitable, this loss of 
function can sometimes be delayed by chronic treatment with corticosteroid medications. Many 
patients require respirators in their late teen years since their diaphragms become fibrotic and too 
weak to perform normal respiration. DMD is a lethal disorder and generally leads to an early 
death of the patients in the third decade of their lives, usually due to respiratory and cardiac 
failure. 
1.2  IMMUNOLOGICAL COMPLICATIONS ASSOCIATED WITH DMD 
 
DMD is primarily a genetic disorder that gives rise to unstable muscle fiber membranes 
and leads to muscle wasting. Nonetheless, high numbers of infiltrating cells, including T cells, 
are also observed in the dystrophic tissues (Fig. 2), indicating that these cells may contribute to 
DMD-associated pathology. In fact, in recent years different studies have suggested an important 
role for the immune system in a dystrophic patient or animal models for actually promoting 
muscle damage. 18 One of the most common animal models to be used in DMD studies is the 
murine model, the mdx mouse, which is a naturally mutated dystrophic model.29-33 The mdx 
mouse, similar to DMD patients, lacks expression of a functional dystrophin protein in its 
skeletal muscle fibers due to a point mutation in the dystrophin gene on its X chromosome, 
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giving rise to a premature stop codon.33 Similar to DMD patients, pathology of the mdx mouse 
skeletal muscle is also associated with inflammation. The observed massive infiltration of 
immune cells, including T cell subsets, to the damaged muscle tissue in an untreated DMD 
patient or the mdx mouse is expected considering the high level of ongoing necrotic events in 
muscle tissues that lead to exposure of all muscle antigens in abnormal levels. 
 
Figure 2: T 
cell infiltration in 
dystrophic mdx mouse 
muscles. Infiltrating 
CD4+ (A) and CD8+ 
(B) T cells are spread 
among damaged muscle 
fibers in DMD patients 
and damaged muscle 
fibers in DMD patients 
and mdx mouse. 
 
However, the fact that depletion of CD4+ and CD8+ T cells or even B cells from the mdx 
mouse system leads to a significant decrease in disease-associated muscle pathology 16-18 
indicates that the loss of muscle mass may not only be a consequence of the defect in dystrophin 
gene. Although it has not been specifically shown experimentally, it is increasingly believed that 
the pathology associated with DMD may also be a result of host’s immune reaction against 
muscle antigens that tend to be exposed at much higher levels than normal, leading to severe 
immune reaction and inflammation in the damaged tissue. Therefore, DMD has progressively 
been considered a disorder that is due to a combination of a genetic defect and immunological 
complications. For this reason, not only induction of expression of a functional dystrophin 
protein in dystrophic muscle should be considered for treating DMD, but different approaches 
for down-regulating immune cell infiltration into dystrophic muscle tissue should be taken into 
serious consideration when treatments are studied and designed for DMD patients.  
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1.3 C. CURRENT TREATMENTS FOR DMD 
 
Although a complete therapy that can cure DMD is not yet available, there are treatments 
that are used to ameliorate the conditions of DMD patients during their relatively short life time. 
Such treatments include drug therapy, using corticosteroids (prednisone, for instance) to slow 
progression of muscle degeneration 34-37 and to lower inflammation in dystrophic muscle. Other 
treatments also exist that mainly improve the quality of life of DMD patients that include using 
assistive devices such as braces and wheelchairs to help patients with their movement and 
mobility, and sometimes using surgical procedures to treat contractures and spinal curvature that 
can become severely painful if not treated.  
Prednisone is usually given to DMD patients starting at early stages of their disease in 
order to minimize pathological phenotype associated with the disease. It is important to 
remember, however, that medications such as prednisone predominantly treat the pathological 
effects of muscular dystrophy rather than the cause of the disease. One important advantage of 
such treatment is that it can be done orally and its effect extends systemically to all muscle 
tissues throughout the body. Side effects of drug treatments may limit their potential benefits, 
however. For example, prednisone and similar drugs are hormones that can temporarily improve 
the lives of DMD patients, but in the long term have side effects 38, including interfering with 
secretion of other hormones needed. Therefore, this treatment, which happens to be one of the 
most common treatments available at this point, may not be fully beneficial for the patients. The 
assistive devices available for DMD patients include braces for weak arms and legs that are used 
for standing up or walking and can help affected boys stay mobile for a slightly longer period of 
time, wheelchairs that are for middle stages of the disease when patients lose ability to walk 
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completely, and ventilators that are used at later stages of the disease when patients have had a 
severe progression of the disease and are no longer able to breathe normally. Finally, there are 
also some selective surgical treatments that may improve the spine problems of DMD patients, 
normally performed at different stages of the disease. 39, 40 However, at this point there is no cure 
for DMD and extensive studies are required to find a way to perhaps restore a functional 
dystrophin gene in muscle tissues of these patients. 
1.4  ONGOING RESEARCH FOR DMD TREATMENT 
 
In addition to the treatments mentioned above that are solely to improve the quality of the 
short lives of DMD patients by slowing down disease progression, there are also treatments that 
are under investigation and some in clinical trials. These treatments are mostly evaluated as 
potential cures for DMD and include cell and gene therapy.  
Cell therapy for DMD is a cell-mediated dystrophin expression in muscles of a 
dystrophic host. In the case of cell therapy in dystrophic muscle tissue, there are muscle stem 
cells, also referred to as satellite cells or myoblasts, from healthy donors that produce normal 
dystrophin protein that can be injected into muscle tissue with defective dystrophin gene, as 
reviewed by Farini et. al. 41 These cells have the potential to fuse with the damaged muscle tissue 
and therefore give rise to muscle fibers that contain a full-length dystrophin gene and produce a 
functional dystrophin protein, as the nuclei of donor cells contain a healthy dystrophin gene. 
Fusion of donor cells and dystrophic muscle fibers has been shown in several studies. In one 
such study, after transfer of muscle stem cells into mdx mouse, they found fused fibers that 
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showed two distinct muscle types with either skeletal muscle characteristics or cardiac muscle 
characteristics,42 indicating that cell therapy indeed has a potential therapeutic effect on 
correcting both skeletal and cardiac muscle tissue in a dystrophic host. In addition to studies in 
which cells from healthy donors were transferred into dystrophic muscle tissue, there are have 
also been studies in which myoblasts from dystrophic donors have been genetically manipulated 
ex vivo to induce dystrophin expression in those cells prior to transferring them into a dystrophic 
mouse or human host.43, 44 
Although these approaches mentioned above have shown promise in the field of cell 
therapy for DMD, there are various challenges that will need to be addressed in the future studies 
in this field in order to be able to consider cell therapy as a successful treatment for DMD. One 
problem with cell therapy is its efficiency, as the donor cells usually need to be directly injected 
nto the damaged muscle tissue and they do not travel very far from the injection sites. Therefore, 
high numbers of injections are required for each muscle to be treated. Researchers are currently 
examining ways to improve the efficiency of injections. In addition to these technical issues, 
there are also obstacles at the cellular level, including the life-span of the transferred cells. As 
demonstrated in one study, transferred cells may only last a few hours in the dystrophic host.45 
The rapid death of transferred cells may, as one study suggests, be due to the infiltration of host 
T cells as part of the adaptive immunity.46 It has been shown, however, that the innate immune 
system may not affect transferred cells in dystrophic muscle tissue.47 In general, the host immune 
system presents a significant barrier to successful cell transplantation, similar to organ or tissue 
transplantation. Various studies have addressed the problem of immune response against 
transferred cells expressing the dystrophin protein in dystrophic hosts using immunosuppressive 
drugs such as FK50648 or Cyclophosphamide. 49 Although immunosuppression is required for 
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preventing immune system-mediated rejection of the transplanted cells, factors such as toxicity 
of the immunosuppressive agent may have negative effects on the host, as was suggested when 
Cyclophosphamide was used in mdx mice undergoing myoblast transplantation.49 To eliminate 
host immunity against transferred cells, irradiation of the host has also been studied, which has 
not been very successful as the cells survived for a short period of time.50 In general, although 
transferring healthy cells with full-length dystrophin gene into dystrophic muscle tissue is a 
promising approach, there are still many obstacles to overcome before this approach can be 
considered a practical therapy for DMD. 
 
Figure 3: Schematic of viral vector delivery to muscle tissue in humans. 
Similar to cell therapy, gene therapy is an approach by which a healthy dystrophin gene 
may be inserted into a viral vector rather than a cell, and can then be transferred into muscle 
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fibers and ultimately nuclei of dystrophic muscle tissue (Fig. 3) and therefore can lead to 
production of a functional dystrophin protein in a dystrophic host. For this purpose, the most 
common means by which the dystrophin gene is transferred into damaged muscle tissue is using 
viral vectors that can infect muscle fibers and transfer the gene of interest into the target tissue. 
Amongst the challenges that are faced in studies on gene therapy for DMD are efficiency of gene 
delivery to target fibers and the host immune system that may lead to rejection of the viral vector 
and the transferred gene. The latter problem has been shown to be to some degree dependent on 
the type of viral vector used and the organism on which the studies are conducted. In the 
following section the gene therapy approach will be discussed in more detail, as the majority of 
subsequent studies explained here deal with dystrophin gene transfer in dystrophic hosts. 
 
1.5 POTENTIAL APPROACHES FOR A CURE: GENE THERAPY 
 
Many researchers worldwide study potential ways to cure DMD. As with any other loss-
of-function genetic disorder with a single-gene mutation, one potential approach to treat DMD is 
therapeutic gene replacement that gives rise to expression of a functional dystrophin protein in 
dystrophic muscle fibers. Dystrophin protein is a large protein with a cDNA of about 14 kb. 
Therefore, it is important to use the vector system with a capacity for this long DNA insert. 
 Some groups have suggested using a shorter version of the dystrophin cDNA to only 
restore a short or “mini-dystrophin” in the treated dystrophic muscle tissues. 51, 52 One of the 
most common vector systems to be used to transfer this mini-dystrophin is the adeno-associated 
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viral (AAV) vector system, which is derived from a small virus from the Parvavirus family and 
has a capacity for a DNA insert of less than 5kb.53 Although expanding packaging capacity is 
being considered, 54-56 at this point the low capacity of AAV will allow for only a highly 
truncated dystrophin cDNA to be transferred into the damaged muscle tissue.  
One of the most considerable advantages associated with the AAV system is the fact that 
these viral vectors do not seem to be pathogenic in humans. There are still many questions that 
remain with regard to the immunological responses of the host against these vectors, as some 
contradictory data on their immunogenicity is available at this point.57-60 Also, although 
successful transgene expression has been achieved with mini-dystrophin in the mouse mdx 
model, it is not yet clear if this small dystrophin protein will be functional in DMD dystrophic 
muscle. Of note, similar truncated versions of dystrophin cause the allelic form of muscular 
dystrophy known as Becker’s muscular dystrophy (BMD). Thus, providing conditions in which a 
full-length dystrophin protein may be transferred into the host system is important. 
 
Figure 4: Schematic of HC-Ad vector carrying dystrophin cDNA.  Depletion of all viral genes from 
adenoviral vector enables scientists to insert a double-stranded DNA of about 30 kb. This will allow for a full-length 
dystrophin cDNA to be inserted into the vector. 
 
A generation of adenoviral vectors referred to as high-capacity adenoviral (HC-Ad) 
vectors, which are depleted of all viral genes and have a DNA-carrying capacity of 
approximately 30 kb61 can be used to transfer this large cDNA (Fig. 4), as has been shown in 
previous work 5, 6, 9, 10, 62.  
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The advantage of this vector over the previous generations of adenoviral vector, 
including first and second generation, in which only segments of viral genes were replaced with 
the DNA insert, is that 1) using this vector system a full-length dystrophin can be expressed in 
the target tissue, whereas with the previous generations a truncated version of dystrophin protein 
was provided to the host, and 2) due to the lack of viral genes, which if present, could allow for 
production of viral proteins in the host, this vector seems to be less immunogenic, as it transfers 
fewer viral antigens. These two characteristics of the HC-Ad vectors make them one of the better 
options available for dystrophin gene therapy. Nonetheless, since it is necessary to use 
adenoviral viruses, referred to as helper viruses, that contain viral genes required for packaging 
of the HC-Ad vectors,63 the final HC-Ad vector product may contain some contaminating helper-
viruses that are capable of producing viral proteins in the host system.  
One important factor affecting the efficiency of vector-mediated dystrophin expression is 
the promoter that controls transgene expression in the desired tissue. When targeting a specific 
tissue or organ in the host, it is crucial to use a tissue-specific promoter, such as the muscle 
creatine kinase (MCK) promoter for muscle cells (Fig. 4), that can result in specific expression 
of the transferred gene only in the desired tissue or organ. Using a tissue-specific promoter will 
prevent potential side effects of expressing a gene in irrelevant tissues and will lower the 
immunogenicity of the transferred gene product, as it is less exposed to the host immune system. 
It is particularly important to control specific tissue targeting and transgene expression because it 
has been shown in various studies that expression of a transgene in organs such as liver, when 
liver is not the target tissue, may lead to high levels of host immune response against the 
transgene product, as has been reviewed by Di Paolo and Shayakhmetov.64  
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 In general, further studies to lower the host immunological reactions against transgene 
product, taking advantage of vectors such as HC-Ad vector that are less immunogenic compared 
to previous generations of adenoviral vectors and using techniques that lead to tissue-specific 
transgene expression are important for successful therapeutic gene delivery. Previous work has 
been done using the HC-Ad vectors to transfer a single or even two copies of full-length 
dystrophin in mdx mouse muscle tissue 5. Even though the vector system used seems to be less 
immunogenic compared to some previously used vectors, expression of dystrophin protein in 
these studies still is not completely successful in the host system, as immunological 
complications interfere with expression of the transgene at a desired rate and for a long period of 
time following vector delivery. 
1.6  OBSTACLES TO GENE THERAPY: IMMUNOLOGICAL 
COMPLICATIONS 
Strategies of gene transfer must contend with the risk of a host immune reaction against 
the products encoded by the transferred gene. Studies on gene therapy for genetic diseases such 
as hemophilia B or DMD, where a gene is either defective or missing, have revealed that 
expression of the therapeutic gene product may be hampered by the host immune system. This 
occurs because the normal mechanisms of self tolerance, such as auto-reactive T cell deletion in 
the thymus during T cell development,65 cannot occur if the self protein is absent or mutated. As 
a result, helper CD4+ T cells may develop that recognize the transferred gene product when it is 
presented by professional antigen presenting cells known as dendritic cells (DCs), and become 
activated. In some cases, particularly when the therapeutic gene product is a soluble protein, 
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these activated T cells can then induce B cell activation and as a consequence neutralizing 
antibodies against the introduced protein are formed, as reviewed by Tarlinton and colleagues,66 
leading to inactivation of its therapeutic role. In addition, the helper T cells can provide signals 
for activation of cytotoxic CD8+ T cells that in turn can induce killing of the cells expressing the 
transferred gene product. Robust activation of the adaptive immune response requires the 
presentation of the foreign protein in the context of an inflammatory response usually mediated 
by the innate immune system. Thus the choice of vector for gene therapy becomes very 
important since DNA and RNA motifs from viral vectors can activate cells of the innate immune 
system, leading to more effective presentation of the gene product to T and B cells. 
With gene therapy, the induction of a host immune response significantly depends on 
factors such as the type of vector used for gene delivery,67-70 the target tissue,71 and the route of 
gene transfer.72-74 Therefore, in a variety of different gene replacement strategies, variable types 
and degrees of immunological response to vector particles and/or transgene product are observed 
that primarily lead to the loss of transgene expression. In response, one approach has been to use 
less immunogenic vectors or to employ specific routes of delivery that lead to more effective 
gene replacement, at least in preclinical models. An example of such an approach is the use of 
the AAV vector for administration of the factor IX gene to hepatocytes of hemophilia B animal 
models, where sustained gene expression, as well as immune tolerance to the transferred gene 
was observed.75, 76 More often, however, high levels of target tissue inflammation are observed 
after gene transfer, with consequent elimination of the gene product. 
Furthermore, even if a preclinical study was successful, the results of subsequent clinical 
trials do not necessarily mirror what was found in animal studies. A recent example comes from 
the clinical trials on hemophilia B, where an AAV vector carrying the factor IX gene was 
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introduced by hepatic gene transfer to participants enrolled in a human study. In this study, 
despite successful pre-clinical animal studies in mice and dogs,76-79 initial human clinical studies 
encountered immunologic challenges. Following gene transfer, elevated liver enzymes were 
observed in these patients, indicating rejection of their transduced hepatocytes, likely due to re-
activation of pre-existing anti-AAV-capsid CD8+ T cells in the recipients.58 Such an outcome 
highlights the importance of generating animal models that better resemble human subjects.   
To achieve the therapeutic goals of gene delivery into a host with a genetic disorder, 
modification of the host immune system to completely accept the transgene product is necessary. 
Various manipulations of the immune system have been attempted in order to minimize the 
immune recognition of transferred gene products to allow for prolonged gene product 
expression.6, 10 One promising approach is to encourage the host immune system to suppress 
undesirable gene product-specific immune responses by stimulating the generation of regulatory 
T (Treg) cells. Similar strategies have been used in studies on autoimmune diseases, including 
type I diabetes, where Tregs have been either generated or stimulated to prevent the undesired 
anti-self immunological responses.80 In fact, considering the link between the unwanted anti-self 
responses in autoimmunity, the responses against a graft in organ transplantation, and the 
responses against a gene product in the case of therapeutic gene transfer, one could compare 
studies in each of these fields to better understand the role of Tregs in down-regulating 
undesirable immune reactions.  
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1.7 IMMUNE TOLERANCE TO SELF- AND NON-SELF ANTIGENS: 
REGULATORY T CELLS 
Tregs are a remarkable and yet not fully characterized T cell subset in the mammalian 
immune system, with  a crucial role in controlling specific immune responses, to self as well as 
to foreign antigens. The adaptive immune system in higher vertebrates is capable of reacting to 
countless non-self antigens. In addition, it is known that auto-reactive T cells survive thymic 
negative selection; the process by which T cells that recognize self-antigens with high avidity are 
eliminated. Such auto-reactive T cells have the potential to cause autoimmune disease. 
 Moreover, a very strong and prolonged reaction to a pathogen may be dangerous to the 
host 81, since this can lead to massive inflammation that can seriously damage the involved 
tissue. Tregs play an essential role in controlling desired immune reactions and preventing 
unwanted autoimmune responses. In fact, the critical role for Tregs in the prevention of 
autoimmunity is best illustrated by the elimination of Tregs in various animal models.82, 83 In 
Scurfy mice, which have a defective foxp3/scurfin gene and therefore lack Tregs,84 for instance, 
a massive lympho-proliferative syndrome is observed, where auto-reactive T cells proliferate 
indefinitely leading to overwhelming autoimmunity.83-85 
Treg sub-populations, including natural and adaptive Tregs, are important in maintaining 
peripheral immunological tolerance, as reviewed by Del.86 Natural Tregs primarily utilize direct 
or cell-to-cell87 interactions with other cells of the immune system, while adaptive Tregs utilize 
indirect or cytokine-mediated87, 88 interactions. Such interactions are mainly with DCs and 
activated conventional (helper or cytotoxic) T cells, as reviewed by Vignali et al.89 Interactions 
of Tregs with DCs through a surface molecule known as LAG-3,90 as well as the effects of the 
secreted products of Tregs such as TGF-ß, IL-10, and IL-3591 on responder T cells are largely 
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responsible for the immunosuppressive role of Tregs. These direct and/or indirect contacts lead 
to activation and proliferation of Tregs and consequently to inactivation of responder T cells. 
The ability of Tregs to down-regulate immunity, which is solely based on the molecular 
characteristics associated with these cells, renders them as promising candidates for the treatment 
of autoimmune diseases,80, 92 and also for the inhibition of inflammatory reactions against a 
transplanted organ,93-95 or a transferred therapeutic gene. 
Molecular Features: In the two Treg sub-populations mentioned above, natural Tregs 
arise in the thymus as a consequence of T cell development, and adaptive Tregs arise in the 
periphery in response to both self and foreign antigens. Natural Tregs are thought to arise as a 
result of partial negative selection in which self reactive T cells are not deleted, but rather 
differentiate into Tregs. Adaptive Tregs can be induced in the periphery by the cytokines TGF-β 
and/or IL-10, or by interaction with peripheral immature DCs expressing low levels of self 
proteins.96 As a result of this diversity there is no single cell surface marker that can be used to 
define Tregs.  In addition, many of the markers associated with Tregs can also be found on 
activated responder CD4+ T cells. To date, a standard approach of most laboratories has been to 
use a combination of different characteristic markers that together are able to specifically 
identify Treg cells efficiently. In addition to the CD4 molecule, these markers include the α 
subunit of interleukin-2 (IL-2) receptor (CD25) in higher levels than on the activated responder T 
cells, cytotoxic T lymphocyte antigen-4 (CTLA-4), membrane-bound transforming growth 
factor-ß (TGF-ß), L-selectin (CD62L), glucocorticoid-induced TNF-related receptor (GITR), 
lymphocyte activated gene-3 (LAG-3), neuropilin-1 (Nrp1),97-99 Galectin-10 (Gal-10),100 and the 
transcription factor forkhead box p3 (Foxp3). Foxp3 seems to be mostly specific to the Treg 
population. Although recent studies have reported transient expression of Foxp3 in activated 
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human T cells,101 this has not been seen in mouse studies. Recently it has also been suggested 
that high expression levels of the cell surface molecule Folate Receptor 4 (FR4) on T cells could 
be used to separate Tregs from activated effector T cells in certain conditions after T cell 
stimulation.102 
Each of the molecules mentioned is important in the function of Treg cells in down-
regulating an immune reaction. For instance, the CTLA-4 molecule interacts with CD80 and 
CD86 molecules on DC and inhibits the ability of these important co-stimulatory molecules to 
bind to CD28 on CD4 T cells that is crucial for T cell activation. TGF-ß is an example of 
immunosuppressive molecules and its signaling along with the help of IL-2 leads to Foxp3 
expression in Tregs.103-105 CD62L is important for the homing of Tregs to the lymph nodes.106 
LAG-3 is a CD4-related molecule with the potential to bind the MHC II molecule on DCs;107, 108 
and Nrp1 is a TGF-beta receptor on the cell surface of Tregs and is suggested to enhance Treg-
DC interaction,97, 99 which are crucial in induction of immunological tolerance. Gal-10 is a lectin 
family member and has been shown to be constitutively expressed in Tregs, at least in humans, 
and has been shown to be essential for the suppressive activity of human-derived Tregs.100 Foxp3 
is a transcription factor that is crucial for the suppression of IL-2 expression, as well as up-
regulation of Treg-associated proteins such as CD25 and CTLA-4.109 In addition to the marker 
molecules that are used to track and/or identify Tregs, there are other markers, such as secreted 
TGF-ß, IL-10, and IL-3591, 110 in the cell culture media that have been used in Treg functional 
assays, in which generally Treg-mediated suppression of responder T cell activity is tested. 
Together, these different molecules make the ongoing research on Tregs in clinically-relevant 
scenarios such as autoimmunity, transplantation, cancer, and therapeutic gene replacement, 
possible. 
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Because Tregs normally occupy only a small portion of the CD4+ T cell pool, it is 
important to find ways to increase Treg number and effect. Positive effects of the 
immunosuppressive drug, rapamycin (RAPA), have been shown on expansion of Foxp3+ Treg 
population,111, 112 both in vitro and in vivo. Aside from its effects on Tregs, RAPA has been 
shown to affect cell growth and metabolism through its interactions with its target protein known 
as the target of rapamycin (TOR),113, 114 which was first characterized in yeast,115, 116 but it has 
also been studied in other eukaryotes, including mammals. In mammals, the protein is named 
mammalian TOR (mTOR). In yeast TOR has been shown to be involved in regulating 
phosphorylation of ribosomal subunits, and therefore, important in regulating protein 
synthesis.117 It has also been studied in terms of the cell cycle process, in which TOR has been 
shown to be a crucial controlling factor.118 In mammals, mTOR regulates similar processes in the 
cell and is currently under investigation. The importance of mTOR in cell growth suggests that it 
may play a role in dystrophic muscles of mdx mice that are undergoing regeneration. Learning 
about the effects of RAPA on both immune system and pathological features associated with 
DMD, as well as understanding mTOR activation in dystrophic muscles has not been previously 
investigated. 
Overall, considering the devastating effects of the immune system on therapeutic gene 
replacement, and on the pathology associated with DMD, it is crucial to understand how immune 
system manipulations may change both host anti-dystrophin immunity and DMD pathology. In 
the following pages, three studies are presented to: 
1) Better understand the anti-dystrophin immunity in dystrophic mice following vector-
mediated dystrophin expression in mdx skeletal muscles.  
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 2) Examine the effects of down regulating the immune system and manipulating mTOR 
activity on dystrophic pathology using the drug RAPA. 
3) Test the hypothesis that RAPA-induced immune suppression may lead to a long-term 
vector-mediated dystrophin expression in mdx muscles. 
In the first study, I have hypothesized that temporal elimination of host immune cells by 
irradiation prior to dystrophin gene transfer leads to a delayed immune response and long-term 
vector-mediated dystrophin protein expression in dystrophic muscles of the mdx mouse. 
In the second study, my hypothesis was that treating the mdx mouse with the 
immunosuppressive drug, rapamycin, will ameliorate the dystrophic muscle pathology by 
lowering inflammation and altering mTOR activation. 
In the third study, I hypothesized that treatment of the mdx mouse with rapamycin prior 
to dystrophin gene transfer will lead to a lower anti-dystrophin immunity and long-term vector-
mediated dystrophin protein expression. 
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2.0  HOST IMMUNOLOGICAL TOLERANCE TO HC-AD VECTOR-MEDIATED 
DYSTROPHIN CDNA TRANSFER BY HOST IRRADIATION  
2.1 RATIONALE 
The following study was conducted to test the hypothesis that an absence of the host 
immune system in the mdx mouse at the time of intramuscular HC-Ad vector-mediated 
dystrophin cDNA transfer will allow for the returning immune cells to recognize the newly 
expressed dystrophin protein as a “self” antigen, thus diminishing, if not completely preventing, 
anti-dystrophin host immune responses leading to successful long-term expression of vector-
mediated dystrophin protein expression. 
 
Copyrighted material; Part of the following section has been published: Gene Ther. 2010 Sep;17(9):1181-90. 
2.2 INTRODUCTION 
Previous studies have found that anti-dystrophin antibodies were induced by HC-Ad 
vector-mediated dystrophin cDNA delivery to muscles of adult mdx mice as early as two weeks 
post-gene transfer.9 This anti-dystrophin immunity is detected even though rare dystrophin-
expressing fibers, known as revertant fibers, are found in mdx muscle.7-9, 119-122 The immune 
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response of a dystrophic host against the transferred dystrophin gene appears to have 
contributions from both humoral and cellular reactions against the vector-mediated expressed 
dystrophin protein. 
The response of the host immune system to the transferred gene reflects the normal 
function of the host defense system against neo-antigens. Because mdx mice do not produce 
dystrophin protein at normal levels, dystrophin may be regarded as a “foreign” antigen when it is 
expressed at higher levels than background in these dystrophic mice. Very little is known about 
the anti-dystrophin immune response raised by dystrophin-deficient recipients to dystrophin gene 
transfer. Therefore, I investigated the anti-dystrophin immune response by manipulating the 
immune system of adult mdx mice through a temporal removal of immune cells prior to vector-
mediated murine dystrophin gene delivery. I utilized complementary approaches to temporarily 
remove the host immune system before gene transfer. First, a low dose of irradiation to 
temporally deplete only the peripheral immune cells was followed by self-reconstitution of the 
host’s peripheral immune cells after gene transfer. Second, a high dose of irradiation was 
followed by reconstitution of the central and peripheral immune system with bone marrow (BM) 
transfer from a syngeneic wild-type donor after gene transfer. The low and high dose irradiation 
allowed me to explore the relative contributions of the peripheral and central components of the 
immune response to recombinant murine dystrophin.  
In addition to using both low and high doses of irradiation, I took advantage of a HC-Ad 
vector that enabled me to study dystrophic host immune responses to a full-length dystrophin 
protein. This was important because when using a mini-dystrophin, for instance, potentially 
immunogenic epitopes have been removed and a complete study of host immune response to 
dystrophin protein may not be achieved.  
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Whole BM from wild-type mice that express endogenous dystrophin protein in striated 
muscle comprises cells that should be fully tolerant to dystrophin protein. By reconstituting the 
peripheral, or peripheral and central immune system after intramuscular dystrophin vector 
transfer, I determined whether the returning or new host immune cells, respectively, recognize 
the full-length murine dystrophin protein as a self-protein. Amongst important players in 
recognizing “self” versus “foreign” antigens in the immune system are Treg cells.82, 83, 85, 123, 124 I 
further explored the role of Treg cells in the peripheral and central immune response to 
recombinant, murine dystrophin protein. 
2.3 METHODS 
Mice: Wild type (C57BL/10J) and mdx (C57BL/10ScSnDmdmdx/J) mice were obtained 
from The Jackson Laboratory (Bar Harbor, ME).  
Serum preparation: Blood was collected from the hearts of mice shortly after sacrifice and 
centrifuged at 10,000 rpm for 15 minutes at 4°C. Supernatant was collected and stored at 4°C. 
Dystrophin high-capacity adenoviral vector: The HC-Ad vector contains a full-length 
murine dystrophin cDNA under the control of the muscle MCK promoter, as well as the left and 
right viral inverted terminal repeats (ITRs) of adenovirus serotype 5 and hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) ‘stuffer’ DNA. The construction of this vector has been fully 
described previously.6, 10 
Mouse irradiation: Mice were irradiated at the age of 5-6 weeks in a linear accelerator 
(LINAC; LINAC Technologies, Orsay, France) irradiator at either a low dose (600 rads) or a 
high dose (900 rads). Specialized care included autoclaved cages, autoclaved food, and acidified 
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water (pH 2.6) from the day before irradiation until the end of each study. In the low-dose 
irradiated group the immune system was allowed to spontaneously reconstitute following gene 
transfer and in the high-dose irradiated group the mice received whole BM from wild-type 
C57BL/10 mice at 12 hours post-gene transfer. 
Intramuscular vector injections: Irradiated and non-irradiated mice received inhalational 
anesthesia with isoflurane and were injected with 1.0-2.0 x1010 genome copies of HC-AdmDYS 
vector intramuscularly in the TA muscle bilaterally. Each muscle was injected with a volume of 
20µl in PBS, using a 28G needle (B-D; Franklin Lakes, NJ). The injections were done in an 
angle and the needle was pulled out slowly to make sure that most of the length of each TA 
muscle receives the vector. 
Total muscle protein extract (TMPE) preparation: Freshly isolated mouse muscle was cut 
in small pieces in TEES buffer (50mM Tris-HCl pH 8.0, 5mM EGTA pH 7.4, 5mM EDTA pH 
8.0, 5% SDS) and incubated on ice for 45 minutes. Samples were then sonicated briefly and 
centrifuged at 14,000 rpm for 20 minutes at 4°C. Supernatant was collected and stored at -80°C. 
Gel electrophoresis and Western blotting: This step was done according to standard 
protocols. The membranes with immobilized murine dystrophin protein used for the assay were 
generated from wild-type C57BL/10J (B10) total muscle protein extracts (TMPE) 
electrophoresed on SDS-PAGE. In brief, TMPE from B10 mice were run on 5% Acrylamide gel 
(Bio-Rad; Hercules, CA) for 3 hours at 110V. Protein samples were transferred from the gel to 
nitrocellulose membrane (Amersham biosciences) for 1.5 hours at 110V at 4°C. The membrane 
was blocked in 5% milk/1% sheep serum/TBST (10mM Tris pH 8.0, 0.15M NaCl, 0.5mM 
Tween-20) overnight at 4°C. The membrane was then cut in pieces with a dystrophin protein 
band in each piece. A set dilution of the sera was used to examine the present or absence of an 
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anti-dystrophin response.  The pieces of membrane were then each incubated with a diluted 
serum sample (1:300) in TBST for 1.5 hours, then with HRP-conjugated sheep anti-mouse IgG 
(GE Healthcare; Piscataway, NJ) diluted in TBST for 45 minutes at room temperature. ECL 
detection reagent (GE Healthcare; Piscataway, NJ) was used to detect the chemiluminescent 
signal and Kodak film was used for visualizing the signal. The initial exposure time was 15-30 
minutes and to confirm the absence of a band in irradiated mice an additional film was exposed 
to the membranes overnight.  
Bone marrow (BM) preparation: Tibia and femur of adult wild type mice were dissected 
out and their surrounding muscle was removed completely. Syringes with 26G needles were used 
to flush the BM out of the bones onto a cell strainer using RPMI-1460 medium supplemented 
with 2% fetal bovine serum (FBS), 5% penicillin/streptomycin, and 10U/ml heparin (Sigma-
Aldrich; St. Louis, MO). BM was then washed with a serum-free RPMI-1460 medium (5% 
penicillin/streptomycin, 20mM HEPES) and counted. For adoptive transfer, cells were re-
suspended in the serum-free medium at a concentration of 2.0x107 cells/ml. Cell suspension (200 
μl) was injected I.V. (4-5x106 cells/mouse) using a 28G needle (B-D). 
Flow cytometry: Single-cell suspensions were prepared by mechanical disaggregation 
through a 40μm cell strainer (Fisher) into PBS. Cells were incubated with rat anti-CD4 (FITC), 
CD25 (APC), and Foxp3 (PE) (ebiosciences; San Diego, CA; 11-0042-82, ,17-0251-81, 12-
5773-80, respectively) and rat anti-CD8 (PE), CD19 (FITC), and CD11c (FITC) (Pharmingen; 
San Jose, CA; 553032, 557398, and 557400, respectively) in FACS staining buffer 
(ebiosciences; San Diego, CA) as indicated by the manufacturer’s instructions. The stained cells 
were then analyzed by a B-D SLR II flow cytometer.  
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Muscle Tissue Processing: Freshly dissected muscle was incubated in 2% 
paraformaldehyde/PBS on ice for 2 hours, then transferred into 30% sucrose overnight at 4°C. 
The next day the muscle tissue was snap-frozen in 2-methylbutane cooled with dry ice and stored 
at -80°C. 
Immunohistochemistry of inflammatory cells: 10μm cryo-sections of muscle samples 
were prepared. Sections were rehydrated in PBS, blocked in peroxidase blocking reagent 
(DAKO Cytomation; Carpinteria, CA) for 5 minutes, and then blocked in 10% goat serum/PBS 
for 1 hour at room temperature. The primary antibody incubation using rat anti-CD4, Foxp3, and 
PD-1 (ebiosciences; San Diego, CA; 16-0041-81, 14-4771-80, and 13-9985-81, respectively) and 
rat anti-CD8 (Pharmingen; San Jose, CA) purified antibodies diluted in 10% goat serum/PBS 
were done for 1.5 hours at room temperature. Sections (except for PD-1 sections because PD-1 
primary antibody was biotinylated) were incubated for 1 hour with secondary biotinylated goat 
anti-rat IgG (Pharmingen; San Jose, CA) diluted in DAKO antibody diluent (DAKO 
Cytomation; Carpinteria, CA). Sections were incubated in ABC Vectastain avidin-HRP detection 
solution (Vector Laboratories; Burlingame, CA) for 30 minutes at room temperature and DAB 
peroxidase substrate solution (Vector Laboratories; Burlingame, CA) for 4 minutes. Eosin 
counterstaining was performed for visualization of muscle fibers. To analyze infiltrating cells in 
each group, the total number of cells per cross-section of vector-injected TA muscles was 
counted and the average number of cells from sections from different mice was calculated.   
Immuno-fluorescence detection of dystrophin and eMyoHC: 10μm cryo-sections were 
rehydrated with PBS, blocked first with avidin and biotin block (Vector Laboratories; 
Burlingame, CA), and then with mouse IgG block (Vector Laboratories; Burlingame, CA), 
according to the manufacturer’s instructions. Incubation with primary anti-DYS or anti-eMyoHC 
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antibodies (Vector Laboratories; Burlingame, CA and Developmental Studies Hybridoma Bank, 
respectively) was done for 3 hours. Sections were then incubated with biotinylated goat anti-
mouse IgG (Pharmingen; San Jose, CA) and tertiary FITC-conjugated donkey anti-goat IgG.  
Statistical Analysis: In all performed studies the statistical analysis was performed by 
student’s t-test, in which a treatment group and a control group, or two treatment groups were 
compared as unpaired sets. Values of variables were presented as the mean with standard 
deviation (SD). In all experiments, P values <0.05 were considered significant. 
2.4 RESULTS 
2.4.1 Low-dose irradiation delays or eliminates anti-dystrophin humoral response 
I first examined the effect of a sub-lethal dose of whole-body-irradiation intended to 
temporarily remove the peripheral immune cells to eliminate the host peripheral immune 
responses against HC-Ad vector-mediated murine dystrophin expression in dystrophic muscles 
of adult mdx mice. In this study 6-week-old mdx mice were irradiated at 600 rads prior to gene 
transfer. Age-matched control groups were either not irradiated prior to dystrophin gene transfer 
or remained untreated for the duration of the study for each time point. Within 24 hours post-
irradiation mice in both vector-injected groups each received an intramuscular injection of HC-
Ad vector carrying the full-length dystrophin cDNA (1.5-2.0 x 1010 genome copies in each 
tibialis anterior (TA) muscle). Groups of treated and untreated mice were sacrificed at 4, 8, or 12 
weeks post-gene delivery for analysis of blood sera for production of anti-dystrophin antibodies, 
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injected muscles for T cell infiltration as well as vector-mediated dystrophin expression, and 
draining lymph nodes for changes in B and T cell populations following gene transfer. 
 
Figure 5: The anti-dystrophin humoral response and loss of muscle dystrophin expression was 
delayed in mdx mice treated with low dose irradiation followed by dystrophin gene transfer using a high-
capacity adenoviral vector. (A) Sera from mdx mice that were irradiated at 600 rads and received an intramuscular 
injection of dystrophin vector (IR + DYS), received an intramuscular injection of dystrophin vector without 
irradiation (no IR + DYS), or received neither irradiation nor dystrophin vector (untreated mdx) were incubated with 
membrane-immobilized dystrophin protein. Sera were collected for analysis at 4, 8, and 12 weeks (Wk) after 
treatment (n=6 for wk 4 and n=5 for wks 8 and 12). No serum indicates a negative immunoblotting control without 
mouse serum primary antibody. DYS-2 indicates a positive immunoblotting control using a monoclonal anti-
dystrophin antibody as the primary antibody. All experimental samples and representative control samples are 
presented here. (B) Dystrophin-expressing fibers per TA muscle section were counted for all experimental mice 
shown in (A) and untreated mdx control mice (n=3). Dystrophin-expressing fibers were labeled on muscle 
cryosections using a monoclonal anti-dystrophin antibody and were counted per section of injected TA muscles. 
Muscle cross-sections from different parts of each injected TA muscle were analyzed and the mean of the counted 
sections from treated and control mice were calculated. Dystrophin-expressing fibers were counted to be 22%, 15%, 
and 7% of total muscle fibers per section at weeks 4, 8, and 12, respectively. Data is expressed as mean ± standard 
error (SE). *(P<0.05) and **(P<0.001) indicate significant differences from untreated mdx control. 
 
At 4 weeks post-gene transfer the mice that had been irradiated prior to intramuscular 
vector injection had no detectable anti-dystrophin humoral response (Fig. 5A, wk4). 
Interestingly, mice that were not irradiated prior to gene transfer all demonstrated an anti-
dystrophin humoral response at as early as 4 weeks post-treatment (Fig. 5A, wk4). 
At 8 weeks post-vector transfer some of the irradiated, vector-injected mdx mice 
demonstrated variable levels of anti-dystrophin humoral immunity. Three of the 5 mice 
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irradiated prior to gene delivery, showed a dystrophin-specific humoral response and 2 mice 
showed no response to dystrophin protein.  All control mice that were not irradiated prior to gene 
transfer demonstrated a strong dystrophin-specific humoral response (Fig. 5A, wk8). In the 
irradiated, vector-injected group, two of the mice showed low responses and one showed a very 
weak response and none of them were as strong as the non-irradiated, vector-injected mice. 
A third group of irradiated, vector-injected mice as well as a third group of non-
irradiated, vector-injected mice were analyzed at 12 weeks post-treatment. Two of 5 irradiated, 
vector-injected mice produced anti-dystrophin humoral responses, while the other three did not 
produce anti-dystrophin antibodies (Fig. 5A, wk12). This contrasted with the control non-
irradiated, vector treated mice, which all showed high levels of dystrophin-specific humoral 
responses (Fig. 5A and Table 1). 
Table 1: Summary of humoral immune response and dystrophin expression data in low- and high-
dose irradiated groups. In this table (+) indicates high level, (+/-) indicates low level, and (-) indicates an absence 
of response or expression. Each symbol represents an individual mouse. 
 
2.4.2 HC-Ad vector-mediated dystrophin expression in low-dose irradiated mdx muscles 
Dystrophin expression in the vector-injected muscles of mdx mice was analyzed by 
immuno-staining of muscle cryo-sections, using an anti-dystrophin monoclonal antibody. 
Differentially-sized, dystrophin-expressing fibers were scattered as both individual fibers and 
  IR 
(600rad)+DYS 
IR 
(900rad)+DYS+ 
B10 BM 
IR (900rad)+ 
B10 BM only 
No 
IR+DYS 
Untreated 
Dys+ 
Fibers 
Wk 4 (+ + + + + ±) (+ + + ± ±) (- - -) (- - -) (- - -) 
Wk 8 (+ + + ± ±) (+ + + ± ±) (- - -) (- - -) (- - -) 
Wk 12 (+ + ± ±) (+ ± ± ± ±) (- - ±) (- - -) (- - -) 
Anti-
Dys 
Ab 
Wk 4 (- - - - - -) (- - - - -) (- - -) (+ + +) (- - -) 
Wk 8 (- - - ± +) (- - - - -) (- - -) (+ + +) (- - -) 
Wk 12 (- - - +) (+ + + + +) (- - -) (+ + +) (- - -) 
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groups of fibers throughout the vector-injected muscle tissue of irradiated mice at 4, 8, and 12 
weeks post-treatment. In contrast, vector-injected control mice that were not irradiated prior to 
gene transfer did not show muscle dystrophin expression above the background level of revertant 
fibers observed in age-matched untreated mdx muscle at any time-point (Fig. 5B and Table 1). 
The number of dystrophin-expressing muscle fibers in the irradiated, vector-treated mice 
decreased with time correlating temporally with the production of detectable antibodies to 
dystrophin protein (Fig. 5B). The reduction in the number of dystrophin-expressing fibers over 
time was observed even in mice that did not produce anti-dystrophin antibody, suggesting that 
the humoral response was not solely responsible for the decrease in dystrophin protein 
expression in the vector-injected muscles.  
2.4.3 B cells in lymph nodes draining vector-injected muscles after low-dose irradiation 
I examined peripheral immune cell reconstitution in the irradiated and non-irradiated, 
vector-injected mice at each time point. Since antibody production and B cell population are 
directly related to each other, B cell levels in the lymph nodes draining the vector-injected TA 
muscles were analyzed to ensure that the peripheral B cells in the irradiated mice had returned to 
levels comparable to untreated mdx mice. At all 3 time-points, the level of B cells, defined by 
CD19 marker, in lymph nodes draining vector-injected TA muscles of irradiated, vector-treated 
mice was not significantly different from untreated mdx mice suggesting a return to the full 
complement of B cells after irradiation (Fig. 6A). The number of B cells in the irradiated, vector-
treated mice, however, increased gradually from week 4 to week 12. The increase in the number 
of B cells coincided with the development of anti-dystrophin antibodies suggesting that the self-
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reconstituted B cells eventually recognized dystrophin protein as a neo-antigen and generated an 
anti-dystrophin immune response.  
At 4 weeks post-treatment, the number of B cells in the draining lymph nodes of the non-
irradiated vector-treated mice was significantly higher than both the irradiated, vector-injected 
and the untreated groups (Fig. 6A), suggesting an early vector-mediated B cell expansion that 
correlated with the high level of anti-dystrophin humoral response observed in vector-treated 
mice. These findings, therefore, indicated that the peripheral immune cells were fully back and 
functional following the whole-body irradiation. 
 
Figure 6: Infiltrating T cells, but not peripheral lymphocytes from vector-injected muscle draining   
lymph nodes in low-dose irradiated mdx mice are different from untreated mdx muscle. (A) The B cell 
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population in draining lymph nodes was analyzed by flow cytometry in low-dose irradiated and non-irradiated mdx 
mice at 4, 8, and 12 weeks post-treatment. Infiltrating CD4+ (B) and CD8+ (C) T cells were examined by 
immunohistochemistry in the treated muscles of low-dose irradiated and non-irradiated mdx mice at the three time 
points mentioned above. Number of mice in each group is the same as in Fig. 1. Data is expressed as mean ± 
standard error (SE). * (P<0.05) indicates significant difference from untreated mdx control. 
2.4.4 T-cell infiltrates in vector-injected muscles after low-dose irradiation 
I also investigated the infiltration of CD4+ and CD8+ T cells in vector-injected muscles of 
mdx mice to assess the cellular immune reaction following recombinant murine dystrophin gene 
expression in the treated muscles. Since muscle infiltration of CD4+ and CD8+ T cells is a 
disease-associated phenotype of mdx mouse muscle and is thought to promote muscle fiber 
necrosis, infiltrating T cells are seen in dystrophic mdx muscles with and without dystrophin 
gene transfer. Therefore, I compared the number of infiltrating T cells in vector-injected muscle, 
with or without irradiation, to age-matched untreated muscle. This allowed me to both assess the 
return of T cells to the peripheral tissues following whole-body irradiation, and investigate the 
level of infiltrating T cells following vector-mediated dystrophin expression.  
Levels of infiltrating CD4+ and CD8+ T cells in muscles of low-dose irradiated, vector-
treated or non-vector-treated mice were not significantly different from untreated mice at week 4 
post-treatment (Fig. 6B and 6C). At week 8 the levels of both CD4+ and CD8+ T cells increased 
in the vector-injected TA muscles of both irradiated and non-irradiated hosts compared to the 
untreated muscle, indicating perhaps the development of a T cell-mediated host immune 
response following dystrophin vector expression at this time point that was not affected by 
irradiation (Fig. 6B and 6C). By week 12, levels of CD4+ and CD8+ T cells had increased in all 
groups to similar levels (Fig. 6B and 6C). Since T cell levels were similar in the low-dose 
irradiated and non-irradiated groups following vector-mediated dystrophin expression, I decided 
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to look at the pattern of T cell infiltration in the muscles of these mice to see if there is a 
difference between the two treated muscles. 
Interestingly, the pattern of T cell infiltration for both CD4+ and CD8+ T cells observed 
on muscle sections was consistently different in the vector-treated, irradiated mice compared to 
the vector-treated, non-irradiated group (Fig. 7). At week 4, T cells were scattered throughout the 
muscle tissue in irradiated vector-injected mdx muscles, similar to those in age-matched 
untreated mdx muscles. In the non-irradiated mice that received the dystrophin vector, however,  
 
Figure 7: Pattern of T cell infiltration in low-dose irradiated, vector-injected muscle is significantly 
different from non-irradiated, vector-injected muscle. Infiltrating CD4+ and CD8+ T cells were examined by 
immunohistochemistry in treated and control muscle at week 4, 8, and 12 post-treatment. This figure shows a 
representative image of week 8 analysis. Arrows indicate single or multiple muscle fibers surrounded with 
infiltrating T cells. 
 
in addition to scattered infiltrating cells, large numbers of cells were seen to cluster around one 
or multiple adjacent fibers, and groups of necrotic muscle fibers were seen as early as 4 weeks 
post-treatment. This observation, plus the fact that dystrophin-expressing fibers were absent in 
non-irradiated, vector-injected muscles as early as 4 weeks post-vector injection suggested that 
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perhaps the dystrophin-expressing fibers were targeted by a specific cell-mediated host immune 
response in the absence of irradiation prior to gene transfer. In the irradiated group a similar 
pattern was only seen in the vector-injected muscles at week 12 post-treatment (data not shown). 
2.4.5 High-dose irradiation delays anti-dystrophin humoral response 
I next examined the effect of removing central and peripheral immune cells of mdx mice 
by 900 rads whole-body irradiation prior to intramuscular dystrophin gene delivery (1.5x1010 
genome copies in each TA muscle). The immune systems of irradiated mice were then  
 
Figure 8: Temporal analysis of degradation of adenoviral capsid proteins following infection of 
muscle cells. C2C12 myoblast cells were infected with adenoviral vector and incubated in myoblast differentiation 
media (DMEM supplemented with 10% FBS and 1% Penicillin and Streptomycin) at 37°C for 48 hours. Samples of 
cells were harvested at different time points to examine viral protein degradation by comparing an intact viral vector 
sample (A) to cell lysis from C2C12 cell cultures (B). At 24 hours only a faint band in position of proteinVI of the 
viral capsid protein was observed and all other proteins had been degraded. 
 
reconstituted by transfer of either wild-type BM from adult B10 donors or mdx BM. Similar to 
the low-dose irradiation studies, mice were analyzed at 4, 8, or 12 weeks post-treatment. I had 
three control groups: one that underwent only gene delivery without receiving other treatments, 
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one that was irradiated and received adoptive transfer of only B10 BM without gene transfer, and 
one that was left untreated for each time point (Table 1).  
I considered what would be an expected time course to clear the initial load of vector 
capsid proteins. To explore this experimentally, C2C12 myoblast cells were infected in vitro with 
Ad vector. Harvested cell samples at various time points for 48 hours were assayed for Ad vector 
capsid proteins by Western blot. Nearly all Ad capsid proteins were degraded in vitro by 24 
hours post-infection (Fig. 8A and 8B). Despite likely differences between viral protein 
degradation in vitro and in vivo, the in vitro results gave me an approximate time point for 
progressing to the in vivo studies. Balancing the desire to maximize the time for viral proteins to 
degrade prior to BM transfer with a need to minimize mouse loss due to high dose irradiation, I 
performed BM transfer at about 15 hours post-gene transfer. BM transfer consisted of tail vein 
intravascular (IV) injections of 4.0-5.0 x 106 BM cells. 
At 4 weeks post-gene transfer none of the mice that had been irradiated and received 
either B10 or mdx BM produced anti-dystrophin antibodies. However, the vector-injected mice 
that had not been irradiated prior to gene transfer produced anti-dystrophin antibodies at this time 
point, similar to the control group in the low-dose irradiation study (Fig. 9A). Unlike the low-
dose study group, however, in which a few mice produced anti-dystrophin antibodies at week 8 
post-treatment, at this time-point none of the irradiated vector-injected mice that received B10 
BM produced an anti-dystrophin humoral response (Fig. 9A). Nonetheless, in the group of mice 
that was irradiated and received mdx BM prior to dystrophin vector transfer, 3 out of 5 mice 
produced anti-dystrophin humoral response at this time point (Fig. 9A). By 12 weeks post-
treatment I observed anti-dystrophin antibody production in all of the irradiated, vector-injected 
mice that received adoptive transfer of B10 or mdx BM (Fig. 9A). Therefore, a high-dose 
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irradiation followed by B10 BM transfer seemed to be the most successful study group in 
delaying the anti-dystrophin host immune response for the longest period of time. Nonetheless, 
the group with mdx BM still had advantages over the non-irradiated, vector-injected group 
because it only partially showed anti-dystrophin humoral response at 8 weeks post-gene transfer, 
compared to the non-irradiated vector-injected group that showed a full anti-dystrophin response 
at as early as 4 weeks post-gene transfer. 
 
Figure 9: The anti-dystrophin humoral response and loss of muscle dystrophin expression was 
delayed in mdx mice treated with high dose irradiation followed by dystrophin gene transfer using a high-
capacity adenoviral vector. (A) Sera from mdx mice that 1) were irradiated at 900 rads and received an 
intramuscular injection of dystrophin vector (IR + DYS+B10 BM), 2) were irradiated and received B10 BM only 
(IR+B10 BM), 3) received an intramuscular injection of dystrophin vector without irradiation (no IR + DYS), or 4) 
received neither irradiation nor dystrophin vector (untreated mdx) were incubated with membrane-immobilized 
dystrophin protein. Sera were collected from treated and control mice at 4, 8, and 12 weeks (Wk) after treatment 
(n=5 for IR+DYS+B10 BM and n=3 for all control groups). No serum indicates a negative control without mouse 
serum labeling. DYS-2 indicates a positive immunoblotting control using a monoclonal anti-dystrophin antibody as 
the primary antibody. All experimental samples and representative control samples are presented here. (B) 
Dystrophin-expressing fibers per TA muscle section were counted for all experimental mice shown in (A) and all 
untreated mdx control mice. Dystrophin-expressing fibers were labeled on muscle cryosections using an anti-
dystrophin monoclonal antibody and were counted per cryosection of treated TA muscles. Muscle cross-sections of 
each vector-injected and uninjected TA muscles were analyzed and the mean of the fibers counted in sections from 
treated and control mice were calculated. Dystrophin-expressing fibers were counted to be 10%, 20%, and 5% of 
total muscle fibers per section at weeks 4, 8, and 12, respectively. Data is expressed as mean ± standard error (SE). 
*(P<0.05) and **(P<0.001) indicate significant differences from untreated mdx control. 
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2.4.6 HC-Ad vector-mediated dystrophin expression in high-dose irradiated mdx muscles 
Dystrophin protein expression in the muscles of treated mdx mice was assessed by 
immunohistological assay, as before. In the high-dose irradiation group I first determined that 
adoptive transfer of B10 BM alone does not give rise to dystrophin-expressing fibers above the 
level in untreated age-matched mdx muscles, for at least 12 weeks post-treatment (Fig. 9B). 
At all time-points post-treatment, dystrophin expression was significantly higher in the 
muscles of the irradiated mice that had received vector and either B10 or mdx BM compared to 
the control groups (Fig. 9B, wk4). At week 4 post-vector injection, the number of dystrophin-
expressing fibers was similar between the two irradiated, vector-injected groups, regardless of 
the source of BM reconstitution. At week 8 post-treatment, however, the level of dystrophin 
expression increased significantly in B10 BM recipient mice that received dystrophin vector, but 
decreased in mdx BM recipient mice that received dystrophin vector (Fig. 9B; wk8). Therefore, 
at week 8 post-treatment the level of dystrophin expression in B10 BM recipient mice was 
significantly higher than all other treated or untreated groups at that time point. The subsequent 
decline in dystrophin expression level at week 12 post-treatment in both BM recipient groups 
correlated with the production of anti-dystrophin antibodies in all the irradiated, BM and vector-
treated mice.  
2.4.7 B cells in the host lymph nodes draining the vector-injected muscles after high-dose 
irradiation and BM transfer 
The lymph nodes draining vector-treated muscles of the high-dose irradiated mice were 
analyzed to examine peripheral lymphocyte levels. The percentage of B cells in the draining 
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lymph nodes was similar among all groups at 4 and 8 weeks post-treatment (Fig. 10A). By week 
12 post-treatment the B cell levels in all groups had decreased (Fig. 10A, wk12). This 
observation mainly indicated that following high-dose irradiation and BM transfer the host 
immune system had successfully been reconstituted and that the donor cells (both B10- and mdx-
derived cells) were in the peripheries at high levels. 
 
 
Figure 10: Infiltrating T cells and peripheral lymphocytes from vector-injected, muscle-draining 
lymph nodes in high dose irradiated mdx mice differ from untreated mdx mice. (A) The B cell population in 
draining lymph nodes was analyzed by flow cytometry in high-dose irradiated and non-irradiated mdx mice at 4, 8, 
and 12 weeks post-treatment. Infiltrating CD4+ (B) and CD8+ (C) T cells were examined by immunohistochemistry 
in the treated muscles of high-dose irradiated and non-irradiated mdx mice at the three time points mentioned above. 
Number of mice in each group is the same as in Fig. 4. Data is expressed as mean ± standard error (SE). * (P<0.05) 
indicates significant difference from untreated mdx control. 
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2.4.8 T-cell infiltrates in vector-injected muscles after high-dose irradiation and BM 
transfer 
I also looked at T cell infiltration in the treated muscles at the same time points. At week 
4 post-treatment, CD4+ T cells were significantly lower in the muscles of the irradiated mice that 
had received dystrophin vector and B10 or mdx BM compared to the non-irradiated, vector-
injected mice, but CD8+ T cells were at comparable levels (Fig. 10B and 10C). Starting at week 
8, however, muscle infiltrating CD4+ and CD8+ T cells were different in the irradiated, vector-
injected mice that received B10 BM compared to those that had received mdx BM. In the B10 
BM recipient mice the level of CD8+ T cells was significantly lower than the control groups, 
where CD8+ T cells in the mdx BM recipient group had increased to a level even higher than the 
non-irradiated, vector-injected mice (Fig. 10B and 10C). The levels of infiltrating CD4+ T cells 
did not change significantly at week 12 post-treatment compared to week 8 in the irradiated, 
vector-injected group that received B10 BM, but increased significantly in the mdx BM recipient 
group to a level that was even significantly higher than the non-irradiated, vector-injected control 
group (Fig. 10B and 10C).  
Infiltrating T cells were observed scattered throughout in the high-dose irradiated, vector-
injected muscles of the B10 BM recipient group at all time points in contrast to clustering around 
specific muscle fibers in non-irradiated, vector-injected muscle. The observed difference in the  
pattern of muscle T cell infiltration between irradiated, vector-injected, B10 recipients and the 
non-irradiated vector-injected control group in the high-dose irradiation study was similar to that 
observed between irradiated, vector-injected group and non-irradiated, vector-injected control 
group in the low-dose irradiation study. In the irradiated, vector-injected group that received mdx 
BM, however, a significant difference was observed compared to the irradiated, vector-injected, 
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B10 BM recipients; large numbers of infiltrating T cells had surrounded groups of muscle fibers 
(Fig. 11). This difference was especially noticeable at week 12 post-treatment. This result clearly 
showed a difference between the two sources of BM that were used to reconstitute the high-dose-
irradiated mice, at a cellular level.   
 
Figure 11: T 
cell infiltration pattern 
difference between B10 
BM recipients and mdx 
BM recipients. 
Infiltrating CD4+ and 
CD8+ T cells were 
examined by 
immunohistochemistry 
in high-dose irradiated, 
vector-injected BM 
recipients and mdx 
recipients at week 4, 8, 
and 12 post-treatment. 
This figure shows a 
significant difference 
between the two BM 
recipients from week 8 
analysis. Arrows show 
small areas with groups 
of T cells in irradiated, 
vector-injected, B10 BM 
recipients. 
 
2.4.9 Regulatory T cells in treated muscles 
An important cell population in modulating immunity is the Foxp3-expressing regulatory 
T cell subset.82, 83 I compared the infiltration of Treg cells in treated muscles at each time point to 
explore a possible role of these cells in modulating the immunity that I observed in treated mdx 
mice. In the low-dose irradiation study, the number of muscle-infiltrating Treg cells was 
comparable at each time point for the vector-treated groups with and without irradiation (Fig. 
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12A). In this treatment groups there was a decrease from week 4 to week 8 followed by an 
increase from week 8 to week 12, a pattern that was also observed in untreated mdx mouse 
muscle, suggesting a contribution of the dystrophic disease progression in muscle. In the high-
dose irradiation study group, however, there was a significant increase in Treg cell infiltration 
starting at week 8 post-treatment in the irradiated, vector-injected mice, that received either B10 
or mdx BM, but not in the non-irradiated, vector-injected mice (Fig. 12B). The number of Treg 
cells further increased at week 12 post-treatment and remained significantly higher in the 
irradiated, vector-injected B10 BM recipients as compared to the non-irradiated, vector-injected 
mice (Fig. 12B). At this time point Tregs increased in mdx BM recipients as well, but this 
increase was not significant compared to their level at week 8. This observation again indicated 
dissimilarity between B10 and mdx BM recipients in terms of host immune system following 
gene transfer.  
 
Figure 12: Regulatory T cell infiltration in treated mdx muscles. Infiltrating Foxp3+ regulatory T cells 
in treated muscles of both low-dose (A) and high-dose (B) irradiated and control groups were analyzed by 
immunohistochemistry at 4, 8, and 12 weeks post-treatment. Number of mice in each group is the same as in Fig. 1 
and Fig.4. Data is expressed as mean ± standard error (SE). * (P<0.05) indicates significant difference from 
untreated mdx control. 
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I also examined the level of muscle infiltration of programmed death-1 (PD-1) expressing 
cells that have been shown to have immune regulatory effects.125 There was no significant 
difference in the number of PD-1+ muscle-infiltrating cells in different treatment groups at 
different time points in mice receiving either low-dose or high-dose irradiation and either B10 or 
mdx BM (data not shown).  
2.5 DISCUSSION 
In studies on therapeutic gene replacement for DMD, the immune response of the 
dystrophic host to vector-mediated dystrophin protein expression is an important limiting factor 
with the potential to cause rejection of recombinant dystrophin. Further understanding of the 
immunological reactions against dystrophin, immune mechanisms that may modulate anti-
dystrophin immunity and manipulations that may reduce anti-dystrophin immune responses in a 
dystrophic host provides the potential to develop approaches designed to prolong dystrophin 
expression in the recipient of therapeutic gene transfer.  
A temporal analysis of the effect of irradiation alone or irradiation combined with BM 
transfer on the immunity against vector-mediated full-length dystrophin expression in mdx 
muscle has not been previously reported. Previous studies have examined the effects on 
dystrophic muscle of adoptive transfer of wild-type BM to irradiated mdx mice,126 muscle 
precursor cells to irradiated mdx mice,127 or BM-derived stem cells to non-irradiated mdx 
mice.128 In the current study I limited the dose of irradiation to a maximum of 900 rads, as in 
other studies,127 to avoid damage to muscle stem cells.129 The use of the HC-Ad vector for gene 
delivery allowed exposure to all epitopes of an expressed full-length murine dystrophin cDNA.  
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In these studies, BM transfer alone to mdx mice did not increase the level of muscle 
dystrophin expression over the background level in untreated mdx mice at any time-point, which 
confirmed the findings of others.126, 130 Therefore, the dystrophin expression observed after 
dystrophin vector delivery following irradiation and BM transfer is vector-mediated.  
Our findings demonstrate that irradiation of the dystrophic mdx host prior to 
intramuscular vector injection led to a delayed, reduced, or absent humoral response against 
dystrophin protein. The changes in anti-dystrophin immunity in treated mice allowed me to study 
the progression of host immunity against dystrophin and its effect on dystrophin expression over 
a period of 12 weeks. The observation that both low-dose and high-dose irradiation delayed the 
development of an anti-dystrophin antibody response is significant compared to the previous 
findings of more rapid host immunity against dystrophin.9  
The delay in development of an anti-dystrophin humoral response was greater in the 
high-dose irradiated group compared to the low-dose irradiated group, as no anti-dystrophin 
humoral response was observed at 8 weeks post-treatment. These results suggest that the more 
complete immune cell depletion (both central and peripheral immune cells) and reconstitution 
with dystrophin-tolerant immune cells results in greater suppression of anti-dystrophin immunity 
induced by dystrophin gene transfer to the dystrophin-deficient mdx host.  
The level of CD4+ and CD8+ T cell infiltration in untreated dystrophic mdx muscle17, 18 
and in dystrophin HC-Ad vector-injected mdx muscle7, 10 has been previously investigated. It has 
been shown that the dystrophic pathology of mdx mouse muscle includes high levels of CD4+ 
and CD8+ T cell infiltration in the damaged tissue that is thought to promote the pathology 
associated with the disease.17, 18 If the immune system in a dystrophic host is not down-regulated, 
the high level of T cell infiltration in the damaged tissue increases following vector injection, due 
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to a natural response of the immune system against the vector and transgene particles. It has been 
shown that specific immune modulations that lead to absent or reduced T cells in the mdx mouse 
can ameliorate the disease process in muscle16, 17 and, in a gene transfer setting, reduce immunity 
against dystrophin protein in the host.6, 10 The present study compared the levels of infiltrating 
CD4+ and CD8+ T cells in vector-injected muscles to untreated mdx mouse muscle at different 
time points. Thus, I evaluated the role that these T cell sub-populations may play in a gene 
therapy setting as both disease and the immunity against recombinant dystrophin progressed. In 
contrast to the observed correlation with the anti-dystrophin humoral response, irradiation prior 
to gene transfer does not seem to affect levels of infiltrating T cells in vector-injected muscles of 
the mdx host during 12 weeks post-treatment, especially in the low-dose irradiation group. 
Interestingly, however, the pattern of T cell infiltration in muscle tissue did appear to be affected 
by irradiation. 
In the early stages after gene transfer, the finding of muscle fibers surrounded and 
invaded by T cells was only observed in the non-irradiated, vector-injected muscles. This focal 
pattern of T cell infiltration was not observed in the irradiated vector-injected muscles of the 
low-dose irradiation study group, the high-dose irradiated, vector-injected, B10 recipients, or in 
untreated mdx mice. Nonetheless, a similar pattern of T cell infiltration to the non-irradiated, 
vector-injected group was observed in the irradiated-vector-injected, mdx BM recipients, and in 
fact it seemed to be more extreme in the mdx BM recipients at wk 12 post-treatment. Double-
staining of T cells and dystrophin in the attacked fibers was not feasible because only necrotic 
fiber remnants remained. Nonetheless, the distinctive pattern of T cell infiltration plus the 
absence of dystrophin-expressing fibers in non-irradiated, vector-injected muscles at early stages 
post-gene transfer suggested that transduced fibers were targeted for immune attack. The same 
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pattern of T cell infiltration has also been observed in previous studies in which transfer of 
muscle precursor cells from dystrophin-normal donors to irradiated mdx mice that had received 
mixed BM from muscle cell-donors and mdx donors, resulted in infiltration of CD4+ and CD8+ T 
cells around dystrophin-expressing muscle fibers at 3-4 months post-treatment.127 In addition, in 
a recent clinical trial, in which AAV vector-mediated expression of a mini-dystrophin protein 
was analyzed in DMD patients, dystrophin-specific T cell responses were observed in some of 
the patients.131 This T cell response was shown to be dystrophin-specific and correlated with a 
loss of dystrophin protein expression in these patients,131 supporting the possibility of a T cell-
mediated rejection of vector-mediated dystrophin expression in the treated mdx mice in my 
studies.  
In addition to the control mice that were treated with the vector without irradiation, I also 
observed a rapid decrease in vector-mediated dystrophin expression in irradiated, vector-injected, 
mdx BM recipients at week 8 following post-treatment, but did not see the same result in the 
irradiated, vector-injected B10 BM recipients. Therefore the presented data indicated that this 
pattern of T cell infiltration, along with the humoral response that was seen in the non-irradiated, 
vector-injected mice and the mdx BM recipient mice precluded successful vector-mediated gene 
expression in the mdx muscle. 
Overall, my analysis of T cell infiltration in treated mdx muscle indicates that even 
though CD4+ and CD8+ T cells infiltrates are found in irradiated, vector-treated mdx muscles, 
this host immune response does not lead to an immediate rejection of dystrophin protein in the 
vector-injected muscles of irradiated mice for at least 12 weeks post-treatment. In contrast, T cell 
infiltration in the vector-injected muscles of non-irradiated mice appeared to reject dystrophin-
expressing fibers, suggested by the pattern of T cell infiltration surrounding muscle fibers and 
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the absence of dystrophin expression as early as 4 weeks post-treatment. This pattern of T cell 
infiltration also correlated with production of anti-dystrophin antibody production in these mice. 
One limitation of the analysis of cellular immunity observed in treated or untreated mdx muscle 
was that the antigens inducing immunity cannot be specifically determined. 
To decipher the mechanism underlying the delayed and diminished host immune 
response observed in both low- and high-dose irradiated groups, I examined infiltration of 
Foxp3+ Treg cells and PD-1+ T cells in treated and control mdx muscles. Only Treg cells were 
different among the groups. I have previously observed infiltrating Foxp3+ Treg cells to be at 
slightly higher levels in untreated mdx mouse muscles compared to age-matched B10 muscles 
(unpublished data). In this study, I observed even higher levels of Treg cells in vector-injected 
muscle of mdx mice 8 and 12 weeks after receiving high-dose irradiation and reconstitution of 
the immune system, especially with B10 BM. This increase in Treg cells suggested their role in 
the diminished anti-dystrophin immune response observed in the setting of central and peripheral 
immune cell depletion followed by reconstitution. In contrast, Treg cells did not appear to play a 
role in the delayed immunity associated with depletion of the peripheral immune cells alone 
followed by self-reconstitution (low-dose irradiation). Taken together, these results suggest a 
role for Treg cells in the suppression of immunity induced by dystrophin vector gene transfer 
followed by reconstitution of the central immune system. The adoptive transfer of whole BM 
from B10 mice may have contributed to the relatively high level of Treg cells in treated muscles 
since the transferred BM is likely to contain cells tolerant to B10 self-antigens, including muscle 
proteins. The exact role of Treg cells in the setting of dystrophin gene delivery to dystrophic 
muscle will require further study. 
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In summary, I show that manipulation of the host immune system by irradiation of the 
adult dystrophic mdx mouse prior to intramuscular HC-Ad dystrophin vector delivery results in a 
delayed and diminished humoral immune response to vector-mediated dystrophin protein 
expression in the adult mdx mouse. The delay in the response correlated with a significantly 
slower rate of elimination of vector-mediated dystrophin protein expression in treated mdx 
muscle compared to muscle of non-irradiated vector-injected mice. Although there are technical 
limitations to determining the antigen specificity of T cells infiltrating muscle, the pattern of T 
cells surrounding and invading muscle fibers suggests that viral vector-mediated dystrophin 
transduction contributes to the antigenic targets, particularly since this pattern of T cell 
infiltration is diminished and delayed by irradiation. The failure to eliminate anti-dystrophin 
humoral and T cell-mediated immunity with both central and peripheral immune depletion 
achieved by irradiation supports the contention that dystrophin expression in dystrophin-
deficient, dystrophic muscle is immune-stimulatory, a finding which has significant ramifications 
for dystrophin gene replacement therapy.  
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3.0   ANALYSIS OF EFFECTS OF RAPAMYCIN (RAPA) TREATMENT ON 
DYSTROPHIC MUSCLES OF MDX MOUSE SKELETAL MUSCLES 
3.1 RATIONALE 
The following study was conducted to test the hypothesis that treatment of dystrophic 
muscles of the mdx mouse with the immunosuppressive drug, RAPA, will ameliorate the 
dystrophic pathology of mdx mouse muscles due to its effects on down-regulating the mdx mouse 
immune system. 
3.2 INTRODUCTION 
The ongoing necrosis of dystrophic skeletal muscle leads to a substantial infiltration in 
the diseased muscle of immune cells, that may be, in part, autoreactive. Previous studies of the 
depletion of CD4+ and CD8+ T cells in the mdx mouse resulted in a significantly lower level of 
muscle fiber necrosis and fibrosis in dystrophic muscle.16, 17 Furthermore, the only proven 
treatment for human DMD, prednisone, is a known immunosuppressant,132 suggesting that 
down-regulation of the immune system in a dystrophic setting may have therapeutic effects. 
RAPA, also referred to as sirolimus, has been widely used for immune suppression in the 
setting of allograft organ or tissue transplantation.133-135 Compared to other immunosuppressant 
 50 
drugs such as cyclosporine A, studies have shown that RAPA has lower toxicity and leads to a 
greater decrease in T cell immunity.136 One of the mechanisms of the selective effect of RAPA is 
an increase in Foxp3+ Treg cell survival and function, which has been shown in vitro and in 
vivo.111, 112 Therefore, I hypothesized that RAPA treatment of the mdx mouse would diminish 
dystrophic pathology of the diseased muscle tissue.  
In mammals RAPA binds to the mammalian target of rapamycin (mTOR), which is a 
highly conserved serine/threonine protein kinase that is expressed in all cell types137 and 
regulates cell growth and protein synthesis.138-140 There are two distinct mTOR complexes 
known as complexes 1 and 2 (mTORC1 and mTORC2, respectively), that vary in both structure 
and function, and respond differentially to nutrients, cellular energy, and growth factors, as 
reviewed by Zhou and Huang.141 The relative importance of mTORC1 and mTORC2 varies 
among different tissues. In skeletal muscle, mTORC1, which is RAPA-sensitive, has been shown 
to play an important role in muscle growth.142, 143 Skeletal muscle mTOR activation levels have 
been followed longitudinally in the mdx mouse.144 However, comparison of mTOR activation 
between age-matched mdx and wild-type B10 mice have not been reported. Findings of these 
studies are important for a better molecular understanding of DMD pathology and can lead to 
potential therapeutic approaches for this disease. 
Because RAPA is a potent immunosuppressant and has the potential to modulate muscle 
growth and regeneration, I studied its effect on the pathology of dystrophic muscle. I examined 
the effects of RAPA on mdx muscle pathology and mTOR activation when administered either 
locally or systemically during the peak of mdx disease-related muscle degeneration and 
regeneration. Given that systemic immune suppression may be associated with adverse 
outcomes, I used two strategies to treat mdx mice with RAPA: 1) local treatment of mdx TA 
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muscles by injection of RAPA-containing microparticles, and 2) systemic treatment of mdx mice 
through RAPA-containing water. The systemic treatment in this study allowed for the analysis of 
the Dia muscle, which is not easily accessible by direct intramuscular injection. 
3.3 METHODS 
Mice: Wild type (C57BL/10J) and mdx (C57BL/10ScSnDmdmdx/J) mice were obtained 
from The Jackson Laboratory (Bar Harbor, ME).  
Cell Culture: Splenocytes were isolated from adult C57BL/10J mice by passing spleen 
tissue through a cell strainer (Fisher) to obtain a single-cell suspension. CD4+CD25+ cells were 
then isolated from the total splenocytes using Miltenyi Biotech separation columns, according to 
the manufacturer’s instructions. In brief, cells were first incubated with an antibody cocktail and 
passed through a negative separation column to remove all cells other than CD4+ cells from the 
splenocytes. The removed cells were irradiated at 3000 rads to be used as antigen presenting 
cells (APCs) in cell cultures. Next, the CD4+ cells were labeled with an anti-CD25 antibody and 
passed through a positive separation column to separate CD25+ cells from other CD4+ cells, to 
obtain CD4+CD25+ cells. These separated cells were then incubated in DMEM medium 
supplemented with 10% FBS, 1% non-essential amino acids, 2mM L-glutamine, 50µM 2-beta 
mercapto-ethanol (2-ME) and 10% peniciline and streptomycine, in standard conditions (37⁰C 
and 5% CO2). Rapamycin was added to the cells at 48 hours post-culture and was added again 
every 4-5 days for a total of 14 days. Cells were harvested after 2 weeks in culture and were 
analyzed by flow cytometry (BD SLR II flow cytometer) for percentage of CD4+CD25hiFoxp3+ 
cells. 
 52 
Total muscle protein extract (TMPE) preparation: Freshly isolated mouse muscle was cut 
into small pieces in TEES buffer (50mM Tris-HCl pH 8.0, 5mM EGTA pH 7.4, 5mM EDTA pH 
8.0, 5% SDS) and incubated on ice for 45 minutes. Samples were then sonicated briefly and 
centrifuged at 14,000 rpm for 20 minutes at 4°C. Supernatant was collected and stored at -80°C. 
Rapamycin-containing PLGA microparticle preparation: RAPA-releasing microparticles 
were produced as previously described.145 In brief, RAPA microparticles were produced using 
the single emulsion-evaporation technique that involved forming an emulsion of an organic 
solution containing rapa and PLGA in a bulk aqueous solution, through high speed 
homogenization (3000 rpm). Following evaporation of the organic solvent (dichloromethane), 
microparticles formed in the aqueous solution were freeze-dried for subsequent use in 
experiments. 
RAPA/H2O preparation and administration: To prepare the mdx mouse drinking water 
containing RAPA (LC Laboratories; Woburn, MA), 1.5mg/kg mouse of RAPA (about 
0.04mg/day/mouse) was dissolved in autoclaved water. Fresh RAPA/H2O was prepared every 7-
10 days. The amount of RAPA added to the mdx mouse drinking water was calculated to 
approximately match the amount of RAPA released from the RAPA-containing microparticles 
that were used in the local treatment group on a daily basis. 
Intramuscular microparticle injection: Six-week-old mdx mice were injected 
intramuscularly with rapamycin-containing microparticles (RAPA beads) in sterile PBS in the 
TA muscle (30µl per TA muscle). Control mice either received empty microparticles (blank 
beads) or were left untreated. Microparticles were injected into the TA muscles with a high-dose 
injection (1mg RAPA per injection) initially, followed by half-dose injection (0.5 mg RAPA per 
 53 
injection) 2 weeks later. Mice were collected 6 weeks after initiation of treatment, thus allowing 
for complete degradation of PLGA microparticles by the time of analysis.  
Gel electrophoresis and Western blotting: Gel electrophoresis and Western blotting were done 
according to standard protocols. Briefly, TMPE from B10 mice was electrophoresed on 5% 
Acrylamide gel (Bio-Rad; Hercules, CA) for 3 hours at 110V. Protein samples were transferred 
from the gel to nitrocellulose membrane (Amersham biosciences) for 1.5 hours at 110V at 4°C. 
The membrane was blocked in 5% milk/1% sheep serum/TBST (10mM Tris pH 8.0, 0.15M 
NaCl, 0.5mM Tween-20) overnight at 4°C. The membrane containing TMPE was incubated with 
primary rabbit anti-mouse total mTOR and phosphorylated mTOR antibodies (Cell Signaling 
Technology; Danvers, MA) in 5%BSA/TBST for 1.5 hours, then with HRP-conjugated donkey 
anti-rabbit IgG (GE Healthcare; Piscataway, NJ) diluted in TBST for 45 minutes at room 
temperature. ECL detection reagent (GE Healthcare; Piscataway, NJ) was used to detect the 
chemiluminescent signal and Kodak film was used for visualizing the signal. The initial exposure 
time was 5-15 minutes. To confirm the absence of a band, an additional film was exposed to 
each membrane overnight. The bands were then analyzed using MCID image analysis software 
(Interfocus Imaging Ltd.; Cambridge, England) to find density of each band. Values for 
phosphor-mTOR were then divided by total mTOR values for evaluation of the level of mTOR 
activation for each mouse. 
Flow cytometry: Single-cell suspensions of cultured cells were prepared by mechanical 
disaggregation through a 40μm cell strainer (Fisher) into PBS. Cells were incubated with rat anti-
CD4 (FITC), CD25 (APC), and Foxp3 (PE) (ebiosciences; San Diego, CA; 11-0042-82, ,17-
0251-81, 12-5773-80, respectively) and rat anti-CD8 (PE), CD19 (FITC), and CD11c (FITC) 
(Pharmingen; San Jose, CA; 553032, 557398, and 557400, respectively) in FACS staining buffer 
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(ebiosciences; San Diego, CA) as indicated by the manufacturer’s instructions. The stained cells 
were then analyzed by a BD SLR II flow cytometer.  
Muscle Tissue Processing: Freshly dissected muscle was incubated in 2% 
paraformaldehyde/PBS on ice for 2 hours, then transferred into 30% sucrose overnight at 4°C. 
The next day the muscle tissue was snap-frozen in 2-methylbutane cooled with dry ice and stored 
at -80°C. 
Immunohistochemistry of inflammatory cells: 10μm cryo-sections of muscle samples 
were prepared. Sections were rehydrated in PBS, blocked in peroxidase blocking reagent 
(DAKO Cytomation; Carpinteria, CA) for 5 minutes, and then blocked in 10% goat serum/PBS 
for 1 hour at room temperature. The primary antibody incubation using rat anti-CD4 and Foxp3 
(ebiosciences; San Diego, CA) and rat anti-CD8 (Pharmingen; San Jose, CA) purified antibodies 
diluted in 10% goat serum/PBS was performed for 1.5 hours at room temperature. Sections were 
incubated for 1 hour with secondary biotinylated goat anti-rat IgG (Pharmingen; San Jose, CA) 
diluted in DAKO antibody diluent (DAKO Cytomation; Carpinteria, CA). Sections were 
incubated in ABC Vectastain avidin-HRP detection solution (Vector Laboratories; Burlingame, 
CA) for 30 minutes at room temperature and DAB peroxidase substrate solution (Vector 
Laboratories; Burlingame, CA) for 4 minutes. Eosin counterstaining was performed for 
visualization of muscle fibers. To analyze infiltrating cells in each group, the total number of 
cells per cross-section of vector-injected TA muscles was counted and the average number of 
cells from sections from different mice was calculated.   
Immunofluoresence staining for necrotic fibers: Muscle fiber necrosis was evaluated 
through fluorescent-conjugated IgG staining of muscle cryo-sections. In brief, muscle cryo-
sections (10µm thick) were re-hydrated with PBS, then blocked with 1% gelatin/1% rabbit 
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serum/PBS for 15 minutes. Samples were next washed with PBS-G wash buffer (0.2% 
gelatin/PBS) and incubated with Alexa-488-conjugated rabbit anti-mouse IgG (Invitrogen; 
Carslbad, CA) for 1 hour, following with PBS-G washes. 
Immunofluorescence staining for regenerating fibers: Muscle fiber regeneration was 
evaluated through staining for embryonic myosing heavy chain (eMyoHC) staining. 10μm cryo-
sections were rehydrated with PBS, blocked first with avidin and biotin block (Vector 
Laboratories; Burlingame, CA), and then with mouse IgG block (Vector Laboratories; 
Burlingame, CA), according to the manufacturer’s instructions. Samples were also briefly 
blocked with 10% goat serum/PBS for 15 minutes at room temperature. Incubation with primary 
anti-eMyoHC antibodies (Developmental Studies Hybridoma Bank) was done for 3 hours at 
room temperature. Sections were then incubated with biotinylated goat anti-mouse IgG 
(Pharmingen; San Jose, CA) and tertiary FITC-conjugated donkey anti-goat IgG. 
Statistical Analysis: In all performed studies the statistical analysis was performed by 
student’s t-test, in which a treatment group and a control group, or two treatment groups were 
compared as unpaired sets. Values of variables were presented as the mean with standard 
deviation (SD). In all experiments, P values <0.05 were considered significant. 
3.4 RESULTS 
3.4.1 RAPA induces Treg proliferation in vitro in the presence of APCs 
Before examining the effects of RAPA on cellular infiltrates and pathology of dystrophic 
muscles in mdx mice, I investigated the effects of RAPA on murine T cells in vitro. Therefore, I 
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isolated T cells from adult wild-type mice to incubate in the presence of RAPA with or without 
APCs. Spleen-derived B10 CD4+CD25+ T cells, separated through cell separation columns 
(Miltenyi biotech), were plated at a density of 250,000 cells per plate in a 6-well plate. Irradiated 
APCs (3000rads) were also added at a 1:1 ratio to the plates. Forty-eight hours after plating the 
cells, RAPA was added and the cells were incubated for 14 days. Fresh RAPA was added every 
48 hours. A significant increase in the number of Foxp3+ CD4+ cells was observed in response to 
RAPA and APCs (Fig. 13). This observed increase in Foxp3+ Treg cells in the presence of 
RAPA was in agreement with the literature on using RAPA for Treg expansion. 
 
Figure 13: In vitro treatment of murine CD4+CD25+ cells with RAPA. Splenocytes isolated from wild-
type C57BL/10 mice were enriched for CD4+CD25+ T cells through column separation techniques and were 
incubated with irradiated antigen presenting cells and treated with RAPA for 2 weeks. Harvested cells were 
analyzed by flow cytometry to evaluate the percentage of CD4+CD25+Foxp3+ T cells following the treatment. (R) 
indicates RAPA and (APC) indicates antigen presenting cells. The blue bar shows the increase in percentage of 
CD4+CD25+Foxp3+ Tregs in the presence of APCs and RAPA.  
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3.4.2 Short-term comparison between injecting mdx muscles with RAPA microparticles 
(slow release) and RAPA solution (fast release) 
Following the in vitro analysis of the effects of RAPA on Treg cells, I performed a short-
term study on whether to study the effects of RAPA on mdx muscle in vivo through injection of 
RAPA-containing microparticles or RAPA solution. This study was designed for confirming the 
benefits of a slow-release system for RAPA in vivo before beginning the long-term study using 
microparticles. For this study, TA muscles of age-matched mdx mice were injected with either 
 
Figure 14: Muscle fiber necrosis and regeneration following short-term RAPA treatment of mdx 
muscles. Two weeks following RAPA treatment, injected TA muscles of mdx mice and age-matched untreated mdx 
control mice were collected for analysis. IgG staining was used to examine the level of necrotic fibers (A and B) and 
embryonic myosin heavy chain (eMyoHC) staining was used to evaluate the level of muscle fiber regeneration (C) 
in muscle tissues. * indicates p value <0.05 and ** indicates p value <0.01.  
 
RAPA microparticles or RAPA solution. Through both injections about 1mg of RAPA was 
injected into each TA muscle and the volume of injection in both groups was 30μl per TA 
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muscle. Mice were sacrificed and TA muscles were collected for analysis at 2 weeks post-
treatment. In my analysis I evaluated the levels of muscle fiber necrosis, muscle fiber 
regeneration, and Foxp3+ cell infiltration between the two treatments and compared them to 
untreated age-matched mdx TA muscles. I observed that both RAPA microparticles and RAPA 
solution had lead to a significantly lower level of muscle fiber necrosis compared to age-matched 
untreated mdx muscle (Fig. 14A and 14B). The level of muscle fiber necrosis in both RAPA- 
treated groups was comparable with the level of RAPA solution group only slightly lower. 
 
Figure 15: Foxp3+ T cell infiltration following short-term RAPA treatment of mdx muscle tissue. 
Two weeks following RAPA treatment, infiltration of Foxp3+ T cells was analyzed through immunohistochemistry 
in the injected TA muscles of RAPA-treated mdx mice. 
  
The decrease in muscle fiber necrosis, naturally lead to a significantly lower level of 
muscle fiber regeneration in both RAPA-treated groups (Fig. 14C). However, the level of muscle 
fiber regeneration in the RAPA-solution-injected muscle was significantly lower than that in the 
RAPA-microparticle-injected muscles, suggesting a more severe effect of the drug on muscle 
fiber growth and protein synthesis when RAPA is injected into the muscles at once. Comparing 
the level of infiltrating Foxp3+ cells in the RAPA-treated muscle tissue indicated a beneficial 
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effect of a slow-release of RAPA over a fast release, as Foxp3+ cells were significantly higher in 
the RAPA-microparticle-injected muscles compared to age-matched untreated mdx muscles, but 
the level of Foxp3+ cells was comparable to the untreated mice in the RAPA solution-injected 
muscles (Fig. 15). Therefore, I decided to use RAPA-microparticles for a local treatment strategy 
in mdx muscles for the rest of my studies. This decision was based on the findings of the more 
detrimental effects of injection of RAPA solution on muscle fiber regeneration and Foxp3+ cell 
survival in the treated muscle tissue.  
 
3.4.3 RAPA lowers infiltrating effector T cells, but not Foxp3+ regulatory T cells in mdx 
muscles 
 Given that infiltration of effector T cells in dystrophic muscles of mdx mice plays 
an important role in the pathology associated with the disease, I hypothesized that RAPA would 
improve the pathology of mdx muscle by reducing the level of infiltrating T cells. Both local and 
systemic treatments began at 6 weeks of age and were continued for 6 weeks prior to sacrifice 
and analysis. TA and Dia muscles were analyzed in the systemic RAPA-treated group, but only 
TA muscles were analyzed in the local RAPA-treated group, because transfer of microparticles 
would not allow for a systemic RAPA delivery. 
 To assess the immunosuppressant effects of RAPA on dystrophic muscle tissue, 
the levels of infiltrating CD4+ and CD8+ T cells in TA muscles of mdx mice were assessed. 
There was a significant decrease in total infiltrating CD4+ T cells in mdx muscles treated with 
local or systemic RAPA compared to untreated or blank bead-injected mdx muscles (Fig. 16A). 
A significant decrease in CD8+ T cells was also observed in mdx TA muscles with systemic 
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RAPA-treatment, but not with local treatment (Fig. 16A). Infiltrating CD4+ and CD8+ T cells 
were observed at highest levels in areas of necrosis in untreated mdx muscle tissue (Fig. 16B). In 
mdx muscles treated with RAPA, however, infiltration of both CD4+ and CD8+ T cells was 
scattered in the tissue (Fig. 16B). In contrast to the effects on CD8+ and total CD4+ T cell levels, 
Foxp3+ T cells were not significantly reduced in mdx TA muscles treated with local or systemic 
RAPA compared to the untreated or blank-bead-treated age-matched muscles (Fig. 16A). This 
observation supported the literature in other tissues on the effects of RAPA on survival of 
Foxp3+ Tregs.111, 112, 146 
 
Figure 16: T cell infiltration in RAPA-treated mdx muscles. Six weeks following either local (Rapa 
Bead) or systemic (Rapa H2O) RAPA treatment of 6-week-old mdx mice, TA muscles were collected for analysis. T 
cell infiltration was evaluated by immunohistochemistry on muscle cross-sections of TA muscles. T cell numbers 
are presented as average number of cells per cross-section (A).  Arrows in panel (B) show areas of muscle fiber 
necrosis with CD4+ or CD8+ T cell infiltrates. * indicates p value < 0.05 and ** indicates p value < 0.01. 
 
3.4.4 RAPA lowers muscle fiber necrosis and regeneration in mdx muscles 
Infiltrating T cells contribute to the pathologic process of muscle fiber necrosis in  
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dystrophic muscles of the mdx mouse and DMD patients.17, 18 Therefore, I quantitatively 
examined the level of muscle fiber necrosis in RAPA-treated and age-matched untreated mdx 
muscles (Fig. 17).  
 
Figure 17: RAPA treatment lowers muscle fiber necrosis in mdx muscles. TA muscles of all RAPA 
treated mice and Dia muscles of systemic RAPA-treated mdx mice only, were collected for analysis six weeks 
following RAPA treatment. Both local and systemic RAPA treatments in lead to significant decreases in muscle 
fiber necrosis in both TA (A) and Dia (B) muscle tissues. IgG staining using a FITC-conjugated anti-mouse IgG was 
used to label necrotic muscle fibers (C). Graphs show average number of necrotic muscle fibers per TA or Dia 
muscle cross-sections. * indicates p value < 0.05 and ** indicates p value < 0.01. 
 
 The total number of necrotic fibers per TA muscle cross-section, as determined by 
incubation with fluorescently labeled IgG, in mice with systemic or local RAPA treatment was 
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significantly less compared to age-matched untreated mdx muscle (Fig.17A and 17C). 
Furthermore, with systemic RAPA treatment, I also observed significantly decreased necrosis in 
the diaphragm (Fig. 17B and 17C).  
Figure 18: Muscle fiber regeneration in RAPA-treated mdx muscles. TA muscles of all RAPA treated 
mice and Dia muscles of systemic RAPA-treated mdx mice only, were collected for analysis six weeks following 
RAPA treatment. Both local and systemic RAPA treatments lead to significant decreases in muscle fiber 
regeneration in both TA and Dia muscles (A). Data from systemic RAPA-treatment study is shown as a 
representative.  eMyoHC staining was used to evaluate muscle regeneration (B). Graph in panel (A) shows average 
number of newly regenerated muscle fibers per TA or Dia muscle cross-sections. * indicates p value < 0.05 and ** 
indicates p value < 0.01. 
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The necrotic muscle fibers in untreated mdx mice were observed in large groups of fibers 
in muscle tissue, whereas in the RAPA-treated mice the fewer necrotic fibers were observed as 
scattered small groups or individual fibers within the muscle tissue (Fig. 17C). 
I also observed a significantly lower level of muscle fiber regeneration, as indicated by 
embryonic myosin heavy chain (eMyoHC) expression in TA and Dia muscle fibers of systemic 
RAPA-treated and TA muscle of local RAPA-treated mice compared to age-matched untreated 
or blank bead-treated mdx muscles (Fig. 18A and 18B). Figure 20 shows representative data 
from the systemic RAPA-treated group.  
 
3.4.5  mTOR activation differs between TA and Dia muscles of mdx mouse 
 The activation of mTOR by phosphorylation in the presence of energy, nutrients, or 
growth factors is known to be important for muscle fiber growth147 and RAPA can block this 
activation. Therefore, I examined the level of mTOR activation in TA and Dia muscles of 6-
week-old (during active necrosis) and 12-week-old (after the peak of active necrosis) age-
matched untreated mdx and wild-type B10 mice by Western blot. Surprisingly, mTOR activation 
was not significantly different between TA muscle of untreated mdx and age-matched B10 mice 
at 6 and 12 weeks of age (Fig. 19A and 19B). In both mdx and B10 TA muscles the level of 
mTOR activation decreased between 6 and 12 weeks of age.  
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Figure 19: mTOR phosphorylation in 6- and 12-week-old mdx versus B10 mice. mTOR activation 
(phosphorylated mTOR over total mTOR) was analyzed in TA and Dia muscles of 6- and 12-week-old mdx mice 
and was compared to age-matched B10 mice. Western blot analysis was used to measure mTOR phosphorylation in 
total muscle protein extracts from muscle samples. (A-D) show average blot intensity of the labeling for each tissue 
type and (E) is a representative image of the blots analyzed. * indicates p value < 0.05. 
 
However, mTOR activation was significantly different between mdx and B10 mice in Dia 
muscle at both 6 and 12 weeks of age (Fig. 19C and D). At 6 weeks of age, mTOR activation 
was lower in B10 Dia muscle than in mdx Dia muscle. I observed that mTOR activation in Dia 
muscles of B10 mice increased from 6 to 12 weeks of age. However, mTOR activation remained 
at similar levels in mdx Dia muscles over the same timeframe.  
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3.4.6 mTOR activation is affected in Dia but not TA muscles of RAPA-treated mice 
 RAPA directly interacts with mTOR in skeletal muscles. Therefore, I compared 
activation of mTOR in skeletal muscles of mdx mice that received systemic and local RAPA 
treatment with age-matched untreated or blank bead-treated mdx mice. RAPA treatment led to a 
significantly lower level of mTOR activation in Dia muscle compared to untreated age-matched 
mdx Dia muscle (Fig. 20A). However, surprisingly, neither local nor systemic RAPA treatment 
resulted in a significant change in mTOR activation in TA muscles of treated mdx mice 
compared to untreated age-matched mdx mice (Fig. 20B and 20C).  
 
Figure 20: mTOR phosphorylation following RAPA treatment. mTOR activation (phosphorylated 
mTOR over total mTOR) was assessed in Dia and TA muscles of systemically RAPA-treated (A and B) and only 
TA muscles of locally RAPA-treated (C) mdx mice at 6 weeks following treatment. This analysis was done by 
Western blot analysis and the graphs show average blot intensity for each tissue type. ** indicates p value < 0.01. 
3.5 DISCUSSION 
In the study presented here I explored the effect of RAPA on inflammation, necrosis, 
regeneration, and mTOR activation in the dystrophic mdx mouse muscles. The effects of 
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different immunosuppressant drugs, including cyclosporine A, prednisone, and deflazacort, have 
been investigated in dystrophin-deficient muscles, as reviewed by Iannitti et.al.148 The study 
presented here, however, is the first report of RAPA treatment for dystrophin-deficient skeletal 
muscle of the mdx murine model for DMD, a model in which a genetic defect in dystrophin 
expression promotes inflammatory cell infiltration in muscle tissue. Others have previously 
shown that administration of RAPA in organ transplantation led to a higher rate of graft 
survival.149-151 
RAPA has been widely used in various studies to expand and/or select for Foxp3+ 
Tregs.111, 112, 146, 152, 153 In contrast to the inhibitory effect of RAPA on proliferation of effector T 
cells, Tregs proliferate and function in the presence of RAPA.111, 112, 146, 147  I show here that 
Foxp3+ cells survive in dystrophic skeletal muscle when RAPA is administered for 6 weeks to 
mdx mice, whereas total CD4+ and CD8+ T cells, decrease significantly. The most prominent 
effect was observed with systemic RAPA treatment. The selective proliferation of Foxp3+ Treg 
cells coupled with a decrease in effector T cells could lead to improvements in morphology and 
function of dystrophic skeletal muscle. 
This study demonstrates that RAPA administration ameliorates the dystrophic phenotype 
of mdx muscle. Based on prior data showing a beneficial effect of RAPA for organ 
transplantation and the knowledge that modulation of immunity ameliorates dystrophic changes 
in muscle in muscular dystrophy, I hypothesized that RAPA would decrease necrosis of 
dystrophic skeletal muscle. I observed a significant reduction of muscle fiber necrosis in both TA 
and Dia muscles of mdx mouse, with a large decrease in the Dia muscle. This is of particular 
importance, because, the level of necrosis in untreated Dia muscle is higher compared to that in 
untreated TA muscle.154  
 67 
The lower muscle fiber regeneration observed in RAPA-treated muscles may be a direct 
result of the reduction in muscle fiber necrosis, because a lower level of necrosis could diminish 
the need for muscle tissue regeneration. In addition, RAPA may inhibit protein synthesis in the 
treated muscle tissue.155 Previous work suggests, however, that when mTOR is selectively 
knocked out in skeletal muscles, muscle fiber regeneration persists in affected muscles.156  
A previous study of mTOR activation in the adult mdx mouse correlates advancing age 
with a reduction in mTOR signaling in mdx muscle between 18 and 24 months of age.144 
However, this previously reported study did not compare mdx with age-matched wild-type B10 
mice. I hypothesized that mTOR activation would be altered in dystrophic muscle because of 
ongoing muscle fiber degeneration and regeneration that characterizes the pathologic process of 
muscular dystrophy. Furthermore, mTOR has been shown to be a crucial regulator of protein 
synthesis, which is required for effective muscle fiber regeneration. In this study, I observed that 
mTOR activation in Dia muscles of 6-week-old and 12-week-old mdx versus age-matched wild-
type B10 mice is significantly different at both time points. mTOR activation is significantly 
higher in mdx mice at 6 weeks of age, when the dystrophic muscle fibers are undergoing a high 
level of regeneration. At 12 weeks of age, when the pathological processes of degeneration and 
regeneration have decrease in mdx dystrophic muscle tissue, however, I observed a significantly 
lower level of mTOR activation in Dia muscles of mdx mice compared to age-matched wild-type 
mice. In fact, mTOR activation increases by age in Dia muscle of B10 mice, but not in mdx mice, 
raising the possibility that the early reduction in muscle fiber regeneration that is observed in Dia 
muscles of mdx mice157 could be related to a failure of mTOR activity to increase. In contrast to 
Dia muscle, mTOR activation was not significantly different in the TA muscle of dystrophic and 
wild-type mice at either 6- or 12-weeks of age. This suggests a difference between the patterns of 
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mTOR activation in TA versus Dia muscles of mdx mice. This is a novel finding that contributes 
to our understanding of the differences in function and progression of pathology between Dia 
and limb muscle of mdx mice.158-160  
In addition to the differences observed in untreated mdx TA and Dia muscles, the 
findings of this study also show a significant difference between mdx TA and Dia muscles in 
response to treatment with the immunosuppressant drug RAPA. The data suggest that Dia 
muscle is more sensitive to the effects of RAPA treatment, supported by a more significant 
decrease in muscle fiber necrosis and a significant reduction in mTOR activation following 
RAPA treatment compared to TA muscles. Interestingly, in previous murine studies, which 
mTOR has been knocked out in skeletal muscles, Dia muscle showed a more severe pathological 
response with a higher level of muscle fiber damage to the absence of mTOR compared to other 
muscles.156 It has also been shown in other studies that protein synthesis in rat hind-limb muscles 
can be independent of RAPA-sensitive pathways,161 indicating that RAPA may not have the 
same effect in Dia and TA muscles. Additional studies of molecules in the mTOR pathway may 
further elucidate the differences between Dia and limb muscle in the mdx mouse.  
In addition to the general effect of RAPA on muscle pathology in mdx mice, I have 
compared local versus systemic administration of RAPA on both disease pathology and mTOR 
activation. Local RAPA administration has been examined in studies that are relevant to 
induction of tolerance in organ transplantation162, 163 and the systemic route of RAPA 
administration has been tested in studies of cancer164 and aging.165 My findings suggest that 
although there were more significant differences in lowering effector T cell infiltration and 
muscle fiber necrosis when RAPA was give systemically compared to when it was given locally, 
at least for the six-week duration of my studies, the positive effects were comparable between the 
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two administration strategies. Nonetheless, it is important to realize the negative effects of each 
strategy, as a systemic treatment affects tissues other than muscles and local treatment is more 
difficult to perform because it requires multiple and repeated injections. Provided the beneficial 
effects of the systemic and local RAPA treatments are comparable, in a disease such as DMD, in 
which every muscle tissue is affected, a systemic treatment may provide a more beneficial 
outcome. However, local RAPA treatment may find greater clinical applicability if preservation 
of individual muscles could improve quality of life of DMD patients.   
In conclusion, the results of the present study, demonstrating the effect of RAPA on 
decreasing inflammation, preserving Foxp3+ T cells, and decreasing necrosis in dystrophic mdx 
muscle tissue, could lead to the further development of treatments for DMD. In addition, the 
findings of novel differences of mTOR activation between TA and Dia muscles in mdx mice, 
both untreated and with RAPA treatment, add to the molecular understanding of the dystrophic 
phenotype.  
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4.0  HOST IMMUNOLOGICAL TOLERANCE TO HC-AD VECTOR MEDIATED 
DYSTROPHIN CDNA TRANSFER BY LOCAL IMMUNE SUPPRESSION. 
4.1 RATIONALE 
The following study was conducted to test the hypothesis that treatment of the mdx 
mouse muscles with RAPA prior to intramuscular HC-Ad vector-mediated dystrophin cDNA 
transfer will result in a decreased level of the host-anti-dystrophin immune responses and a long-
term vector-mediated dystrophin protein expression in treated muscles.  
4.2  INTRODUCTION 
The host immune system is a major obstacle to successful transfer of a full-length 
dystrophin cDNA to dystrophic muscles of the mdx mouse model of DMD. Immune suppression 
in a dystrophic host may prevent host immunity against recombinant dystrophin protein and 
vector particles. However, systemic immune suppression can cause many side effects. One 
important side effect is an increased vulnerability to infectious pathogens and tumor growth. 
Therefore, it is important to find ways to suppress the immune system locally at a desired site of 
transgene expression, for instance, to avoid the negative consequences of a systemic down-
regulation of host immunity.  
 71 
One approach for the delivery of a chemical or a drug to an organ or tissue locally is the 
use of biologically degradable micro-particles that carry the desired drug to the target tissue. 
Injection of such micro-particles to the site of interest is the most common way to achieve site-
specific delivery. Advantages of this approach include slow release of the drug and thus avoiding 
multiple injections in a short period of time. One example of using beads for immunosuppressant 
drug delivery is in studies of autoimmunity and organ or tissue transplantation.166, 167 As an 
analogous approach to promote the success of dystrophin gene transfer, I hypothesized that 
RAPA-carrying beads would suppress anti-dystrophin immunity in dystrophic mdx muscle tissue 
treated with dystrophin vector delivery.  
Therefore, the aim of the following study was to suppress the mdx mouse immune system 
only in TA muscles that receive dystrophin-carrying high capacity adenoviral (HC-Ad) vector to 
induce immune suppression and prevent specific immune responses to vector antigens and 
transgene product at the site of dystrophin protein expression. The PLGA micro-particles used in 
my study were relatively large with an average diameter of about 15 µm (compared to smaller 
forms that are about 4 µm in diameter). Therefore, I did not expect them to move in and out of 
the muscle tissue freely or to be easily picked up by circulating DCs, thus achieving a local 
treatment. 
I used adult 6-week-old mdx mice in this study to assure that the host immune system was 
fully developed at the time of treatment. Six weeks following RAPA and dystrophin vector 
treatments mouse sera were examined for anti-dystrophin antibody production by the host and 
vector-mediated dystrophin expression was also evaluated in treated muscles. 
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4.3 METHODS 
Mice: Wild type (C57BL/10J) and mdx (C57BL/10ScSnDmdmdx/J) mice were obtained 
from The Jackson Laboratory (Bar Harbor, ME).  
Total muscle protein extract (TMPE) preparation: Freshly isolated mouse muscle was cut 
in small pieces in TEES buffer (50mM Tris-HCl pH 8.0, 5mM EGTA pH 7.4, 5mM EDTA pH 
8.0, 5% SDS) and incubated on ice for 45 minutes. Samples were then sonicated briefly and 
centrifuged at 14,000 rpm for 20 minutes at 4°C. Supernatant was collected and stored at -80°C. 
Rapamycin-containing PLGA microparticle preparation: RAPA microparticles were 
produced as described.145 In brief, RAPA microparticles were produced using the single 
emulsion-evaporation technique that involved forming an emulsion of an organic solution 
containing rapa and PLGA in a bulk aqueous solution, through high speed homogenization (3000 
rpm). Following evaporation of the organic solvent (dichloromethane), microparticles formed in 
the aqueous solution were freeze-dried and used in my experiments. 
Intramuscular microparticle injection: Six-week-old mdx mice were injected 
intramuscularly with rapamycin-containing microparticles (RAPA beads) in sterile PBS (30µl 
per TA). Control mice either received empty microparticles (blank beads) or were left untreated.  
Gel electrophoresis and Western blotting: This step was done according to standard 
protocols. The membranes with immobilized murine dystrophin protein used for the assay were 
generated from wild-type C57BL/10J (B10) total muscle protein extracts (TMPE) 
electrophoresed on SDS-PAGE. In brief, TMPE from B10 mice were run on 5% Acrylamide gel 
(Bio-Rad; Hercules, CA) for 3 hours at 110V. Protein samples were transferred from the gel to 
nitrocellulose membrane (Amersham biosciences) for 1.5 hours at 110V at 4°C. The membrane 
was blocked in 5% milk/1% sheep serum/TBST (10mM Tris pH 8.0, 0.15M NaCl, 0.5mM 
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Tween-20) overnight at 4°C. The membrane was then cut in pieces with a dystrophin protein 
band in each piece. A set dilution of the sera was used to examine the present or absence of an 
anti-dystrophin response.  The pieces of membrane were then each incubated with a diluted 
serum sample (1:300) in TBST for 1.5 hours, then with HRP-conjugated sheep anti-mouse IgG 
(GE Healthcare; Piscataway, NJ) diluted in TBST for 45 minutes at room temperature. ECL 
detection reagent (GE Healthcare; Piscataway, NJ) was used to detect the chemiluminescent 
signal and Kodak film was used for visualizing the signal. The initial exposure time was 15-30 
minutes and to confirm the absence of a band in irradiated mice an additional film was exposed 
to the membranes overnight.  
Muscle Tissue Processing: Freshly dissected muscle was incubated in 2% 
paraformaldehyde/PBS on ice for 2 hours, then transferred into 30% sucrose overnight at 4°C. 
The next day the muscle tissue was snap-frozen in 2-methylbutane cooled with dry ice and stored 
at -80°C. 
Immunohistochemistry of inflammatory cells: 10μm cryo-sections of muscle samples 
were prepared. Sections were rehydrated in PBS, blocked in peroxidase blocking reagent 
(DAKO Cytomation; Carpinteria, CA) for 5 minutes, and then blocked in 10% goat serum/PBS 
for 1 hour at room temperature. The primary antibody incubation using rat anti-CD4 and Foxp3 
(ebiosciences; San Diego, CA) and rat anti-CD8 (Pharmingen; San Jose, CA) purified antibodies 
diluted in 10% goat serum/PBS were done for 1.5 hours at room temperature. Sections were 
incubated for 1 hour with secondary biotinylated goat anti-rat IgG (Pharmingen; San Jose, CA) 
diluted in DAKO antibody diluent (DAKO Cytomation; Carpinteria, CA). Sections were 
incubated in ABC Vectastain avidin-HRP detection solution (Vector Laboratories; Burlingame, 
CA) for 30 minutes at room temperature and DAB peroxidase substrate solution (Vector 
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Laboratories; Burlingame, CA) for 4 minutes. Eosin counterstaining was performed for 
visualization of muscle fibers. To analyze infiltrating cells in each group, the total number of 
cells per cross-section of vector-injected TA muscles was counted and the average number of 
cells from sections from different mice was calculated.   
Statistical Analysis: In all performed studies the statistical analysis was performed by 
student’s t-test, in which a treatment group and a control group, or two treatment groups were 
compared as unpaired sets. Values of variables were presented as the mean with standard 
deviation (SD). In all experiments, P values <0.05 were considered significant. 
4.4 RESULTS 
4.4.1 RAPA treatment does not prevent anti-dystrophin antibody production following 
vector-mediated dystrophin expression in mdx muscles 
In order to examine if injection of RAPA-containing beads into mdx muscle could 
suppress humoral host immunity against vector-mediated dystrophin expression in the treated 
tissue, I examined the sera from RAPA-treated, vector-injected mice for production of anti-
dystrophin antibodies. I compared the sera from treated mice to sera from mice that had received 
blank bead injections prior to an intramuscular dystrophin vector injection in the TA muscles. To 
assess production of anti-dystrophin antibodies in the sera of the treated mice I prepared total 
muscle protein extracts from wild-type C57BL/10 mice that do produce dystrophin protein in 
their muscle tissue, and immobilized that on a nitrocellulose membrane, which was then 
incubated with sera from the treated mice. A secondary anti-mouse IgG was used to detect any 
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mouse antibodies that may have been bound to the membrane-bound muscle proteins, including 
dystrophin protein.  
 
Figure 21: Anti-dystrophin humoral response in mice that had received RAPA or blank 
microparticle injections prior to dystrophin vector injection. Mice were treated at 6 weeks of age and dystrophin 
vector was injected into TA muscles of RAPA or blank bead-injected mice at about 24 hours following bead-
injections. Mice were sacrificed and treated muscle tissue was collected 6 weeks post-treatment. Sera were analyzed 
for anti-dystrophin antibody production. A monoclonal anti-dystrophin antibody (Dys-2) was used as a positive 
control. Negative controls were sera from untreated age-matched mdx mouse and a sample with no serum incubation 
(secondary staining, only).   
 
 Surprisingly, I observed that all of the mice that had received RAPA treatment prior to 
dystrophin vector transfer produced anti-dystrophin antibodies (Fig. 21). The mice that had been 
injected with blank beads also produced strong anti-dystrophin antibody, as expected, and at 
higher levels compared to the mice that received RAPA treatment and dystrophin vector 
injection. This observation suggested that local RAPA treatment did not lead to a complete 
elimination of host immune response against vector-mediated dystrophin protein expression in 
the treated muscle tissue, as all treated mice did produce anti-dystrophin antibody following 
vector-mediated dystrophin expression. Nonetheless, RAPA treatment down-regulated host 
immunity against dystrophin protein by lowering the level of anti-dystrophin antibody 
production compared to the blank bead-treatment in dystrophin vector-injected mdx mice. 
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4.4.2 RAPA treatment reduces infiltration of effector T cells, but not regulatory T cells in 
muscle 
To examine the effect of RAPA on T cell infiltration following vector-mediated 
dystrophin expression, levels of CD4+, CD8+, and Foxp3+ cells were evaluated in TA muscles of 
mdx mice treated with RAPA or blank beads prior to dystrophin vector injection. T cell 
infiltration was analyzed through immunohistochemistry and average cell numbers per TA cross-
section were compared. CD4+ T cells were significantly lower in RAPA bead-treated, vector-
injected and age-matched untreated mdx TA muscles compared to blank bead-treated, vector-
injected TA muscles (Fig. 22). CD8+ T cells were also at lower levels in both RAPA bead-
treated, vector-injected and untreated mdx muscles compared to blank bead-treated, vector- 
Figure 22: T cell 
infiltration in RAPA bead- 
or blank bead-treated, 
dystrophin vector-injected 
mdx TA muscles. Six 
weeks following treatment 
TA muscles were analyzed 
for T cell infiltration 
following vector-mediated 
dystrophin expression. T 
cells were detected through 
immunohistochemistry 
staining and were counted 
and averaged per TA cross-
section.  n=6 for RAPA 
bead-injected and n=4 for 
blank bead-injected mice. * 
indicates p value < 0.05. 
 
injected muscles, but the difference was only significant between untreated and blank bead-
treated groups. The difference in CD8+ T cells between RAPA bead-treated and blank bead-
treated groups did not reach significance (p=0.13). Interestingly, however, the level of Foxp3+ T 
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cells was not lower in RAPA bead-treated muscles compared to blank bead-treated or untreated 
muscles (Fig. 22). 
4.4.3 RAPA treatment is not associated with a higher level of vector-mediated DYS 
expression in mdx muscles 
Through immunofluorescence staining for dystrophin protein in muscle cross-sections, I 
observed vector-
mediated dystrophin 
expression in RAPA 
bead-treated muscles 
that was higher than 
the background level 
of dystrophin 
expression in 
revertant fibers in 
untreated age-
matched muscles 
(Fig. 23).  
 
 
Figure 23: Vector-mediated dystrophin protein expression in RAPA bead- or blank bead-treated 
mdx TA muscles. Six weeks following treatment TA muscles were analyzed for dystrophin protein expression. 
Dystrophin-expressing fibers were counted on cross-sections of TA muscles from various longitudinal positions on 
each TA muscle and were averaged per TA section (A). Detection of dystrophin-expressing fibers was done by 
immuno-fluorescent staining using a monoclonal anti-dystrophin primary antibody (Dys-2) and a fluorescent-
conjugated secondary antibody for visualization of the dystrophin-expressing fibers (B). 
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Nonetheless, surprisingly, the mice that were injected with blank beads and dystrophin 
vector showed a comparable but slightly higher level of dystrophin expression at 6 weeks 
following treatment (Fig. 23).  
4.5 DISCUSSION 
Evasion of the host-anti-dystrophin immune response is required for successful 
therapeutic gene replacement in DMD patients as well as in animal models of DMD including 
the mdx mouse.8, 9, 168-170 Therefore, down-regulation of the host immune system prior to and 
during vector transfer and vector-mediated gene expression is an important factor in finding a 
practical approach to transfer a healthy dystrophin gene into muscles of the dystrophic host. 
The immunosuppressive drug, RAPA, has been successfully used in other applications, 
including organ and tissue transplantation, in which suppression of immunity is desired.147, 171 A 
wide range of transplantation studies, from lung to bone marrow transplantations, have showed 
beneficial effects of using RAPA to reduce or eliminate both graft-versus-host and host-versus-
graft responses that are common in transplanted patients. Mechanisms of action include 
inhibition of effector T cell activation and proliferation, Treg expansion, or prevention of 
cytotoxic cytokine production.172-174 Considering the beneficial advantages that RAPA has in 
down-regulating host immunity against neo-antigens in organ and tissue transplantation, I 
pursued the investigations presented in this section to see if the effects of RAPA on the immune 
system of the mdx host may benefit vector-mediated expression of dystrophin. 
Although RAPA is a potent immuosuppressive agent, other effects of the drug may limit 
its utility. It was previously reported that RAPA may prevent protein expression through binding 
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to its target protein, mTOR in mammals, which is a major regulator of cell growth and protein 
synthesis in response to energy and nutrients.175-177 Therefore, it is considered that the 
immunosuppressive effects of RAPA and its inhibitory effects on protein expression could have 
opposite effects on vector-mediated dystrophin expression in mdx muscles. This may explain 
why RAPA-treated, vector-injected mdx muscles did not show a higher level of vector-mediated 
dystrophin expression.  
Nonetheless, data presented in this study clearly showed that the immunosuppressive 
characteristic of RAPA indeed had a positive effect on decreasing antibody production in 
dystrophin vector-injected mice, compared to the blank bead-injected, dystrophin vector-injected 
mice. I observed that although all RAPA- and blank-bead-treated mdx mice developed an anti-
dystrophin antibody response following vector-mediated dystrophin expression, RAPA-treated 
mice showed a significant reduction of the anti-dystrophin antibody response. 
Furthermore, similar to the effect of RAPA on lowering host humoral immunity against 
vector-mediated dystrophin protein expression, T cell infiltration in RAPA bead-treated mdx 
muscle tissue was also affected. As shown previously, vector-mediated dystrophin expression in 
mdx muscles leads to effector T cell infiltration at levels significantly higher than untreated mdx 
muscles.178 In agreement to the previous findings, I show here that when the mice were treated 
with blank beads prior to dystrophin vector transfer, a significantly higher level of CD4+ and 
CD8+ T cells infiltrate in the treated muscle tissue. Nonetheless, RAPA treatment prior to 
dystrophin vector transfer leads to infiltration of CD4+ and CD8+ T cells at levels comparable to 
the untreated mdx muscles, indicating the positive effect of RAPA on down-regulating host 
cellular immunity following vector-mediated dystrophin expression. 
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In addition to the effects of RAPA on vector-mediated gene expression, a slight effect of 
the RAPA-encapsulated PLGA beads in the injected muscle tissue has to be considered as well, 
as the PLGA beads are acidic, therefore, affecting the pH of the injected site. Previous studies 
have indicated that lowering the pH may promote gene expression, as one study showed 2-14 
fold increase in protein synthesis when pH was lowered from 7.0 to 5.0 in bacterial systems.179 
Therefore, the effect of the beads on the pH of the injected muscle tissue is an important factor in 
analysis of the presented findings. My data shows that RAPA beads and blank beads give 
comparable results in terms of vector-mediated dystrophin expression; they both lead to 
significantly higher level of dystrophin expression in the injected muscle tissues. In fact, vector-
mediated dystrophin expression appears slightly lower in the mdx muscles that had received 
RAPA beads compared to those receiving only blank beads. Possible explanation for this 
observation is that the slightly acidic nature of the beads promotes successful vector-mediated 
gene expression, while RAPA prevents gene expression in the injected muscle tissue. 
Overall, data shown here indicate that regardless of its immunosuppressive effects in 
treated tissues in cases such as organ or tissue transplantation, RAPA may not be a beneficial 
adjunct to vector-mediated gene therapy that depends on expression of the recombinant gene in 
addition to successful gene delivery and persistence.  
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5.0  CONCLUSIONS AND IMPLICATIONS 
Recent studies on DMD have extensively focused on better understanding the disease2, 22, 
24, 119, 180-182 and evaluating potential therapeutic approaches4, 5, 7, 9, 10, 36, 52, 183 to cure this 
devastating lethal disorder. A clear molecular knowledge on the mechanism of the disease is 
crucial for enabling us to find the best possible treatment for DMD. In addition, evaluation of 
potential barriers for successful treatment and understanding the mechanisms behind these 
barriers is equally important toward a goal of ameliorating the disease phenotype. In the work 
presented here, the major goal has been to assess immunological problems that are associated 
with both dystrophin gene therapy and the disease-associated pathology. To accomplish these 
aims, I used irradiation to test the effect of a temporal elimination of immunity as an adjunct to 
gene transfer. I also studied the effects of the immunosuppressive drug, RAPA, on both untreated 
and dystrophin vector-injected mdx muscles. 
5.1 IRRADIATION FOR GENE THERAPY 
Irradiation has been widely used for down-regulation of undesired immunity in mice.50, 
184-188 In my studies, I observed that irradiation can delay and reduce host immunity against 
vector-mediated dystrophin expression in adult mdx mice; an observation that was not reported 
previously. Through this irradiation-mediated transient removal of the host immune system, I 
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was able to temporally analyze the developing anti-dystrophin host immune response. The 
findings of this aim are particularly important in understanding various aspects of host anti-
dystrophin immune response in dystrophic mice, with an ultimate goal of a better understanding 
of an anti-dystrophin immune response in DMD patients.  
5.2 RAPAMYCIN IN DYSTROPHIC MUSCLE 
Immune suppression is currently considered one of the common treatments for a DMD 
patient.34, 37, 38, 189, 190  Through analyzing the immunosuppressive effects of RAPA on dystrophic 
mdx muscles, I learned that although RAPA may have negative effects on cell growth and 
protein synthesis, it has significant benefits on dystrophic muscle phenotype and has the potential 
to be considered as a beneficial treatment for DMD patients suffering from severe muscle fiber 
necrosis and T cell infiltration in their muscle tissue. As a valuable consequence of treating mdx 
mice with RAPA, I also observed that there are major differences in mTOR activation between 
TA and diaphragm muscles in mdx mice with and without RAPA treatment. This finding is novel 
and requires a more in-depth analysis of the mTOR pathway in dystrophic muscle. The results of 
this study are important for future work on both therapeutic and molecular aspects of DMD. 
5.3 RAPAMYCIN FOR GENE THERAPY 
Since RAPA has been successfully used in down-regulating host immunity in organ and 
tissue transplantation,134, 151, 167, 172 I conducted studies, in which RAPA was used to down-
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regulate anti-dystrophin immunity in dystrophin vector-injected mdx mice. Aside from the 
positive therapeutic effects that RAPA seems to have for treating dystrophic muscles, it may not 
be a beneficial candidate for using as an immunosuppressive drug along with gene delivery in 
mdx muscles. In fact, the characteristic of RAPA that interferes with protein synthesis seems to 
directly affect vector-mediated dystrophin expression, and therefore does not allow for 
successful therapeutic gene replacement in these mice.   
Overall, I expect that the studies presented here provide beneficial data on the immunity 
aspects of both therapeutic gene replacement in dystrophic muscle, and DMD phenotype. Of 
course, more questions will follow the findings explained in this thesis that will require further 
in-depth investigation. Potential future studies may deal with a further analysis of 1) the 
differences observed between peripheral and central anti-dystrophin host immune responses 
following vector-mediated dystrophin expression in mdx muscles, 2) the activities of proteins 
upstream and downstream of mTOR in dystrophic muscles, 3) the effects of immunosuppressive 
drugs other than RAPA on dystrophin gene transfer in the mdx mouse, and other additional 
questions that can shed more light on each of these matters. At this point, I hope that the results 
of the studies presented here will contribute toward the quest to find a cure for DMD patients. 
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